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1. Introduction 
1.1 – ANTIMICROBIAL PEPTIDES: GENERAL FEATURES AND 
INNATE IMMUNITY 
Antimicrobial peptides (AMPs) are evolutionally conserved molecules found in 
bacteria, fungi as well as in higher eukaryotes (Nakatsuji and Gallo 2012), 
(Ageitos, Sanchez-Perez et al. 2016), and act as an immediate host response to a 
wide spectrum of microorganisms, before the adaptive immune system is activated 
(Pasupuleti, Schmidtchen et al. 2012). In mammals, AMPs are generally 
synthesized in tissues exposed to the external environment, such as the skin, the 
intestine, the lungs and the circulating white cells. AMPs are encoded by genes, 
ribosomally synthesized as pre-propeptides of 60-170 amino acids, and then 
processed by different kind of proteases to the active mature peptides. The innate 
immune system can respond in a matter of hours before the adaptive immunity is 
activate. Indeed, the time needed to synthesize and process a pre-propeptide is 
certainly shorter than the time required to produce two heavy and two light 
immunoglobulin chains, the production of which also requires the differentiation 
of a memory cell to a plasma cell. This prompt response is very important 
considering the difference in the growth rate between a bacterium (generation time 
20-30 min) and a lymphocyte (24-48 hours of doubling time). In addition, another  
advantage of AMPs as key molecules of the innate immunity is that they can 
function without high specificity (Boman 1995).  
AMPs expression can be constitutive or inducible upon inflammation or infection 
through a Toll-like receptor-mediated signaling transduction cascade. This 
pathway can be triggered by microbial components (e.g. lipopolysaccharides, 
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LPS) and leads to the activation of NF-kB-controlled genes, including those 
encoding for AMPs (Thaiss, Levy et al. 2016).  
Recently, in addition to their antimicrobial activity, AMPs from higher eukaryotes 
have been found to act as intracellular signaling molecules and to coordinate the 
innate and adaptive host defense responses (Hemshekhar, Anaparti et al. 2016), 
influencing processes like: (i) cytokine release (Afacan, Yeung et al. 2012); (ii) 
immune cell differentiation (Davidson, Currie et al. 2004); (iii) chemotactic 
activity (Mookherjee and Hancock 2007); wound-healing and angiogenesis (Wu, 
Wong et al. 2010). Some of these properties would be considered pro-
inflammatory, but AMPs actually can suppress TLR signaling responses, by 
blocking the LPS-stimulated production of cytokines, such as the tumor necrosis 
factor-alpha (TNF-α). This would hamper the emergence of septic shock 
syndrome in animal models (Bowdish and Hancock 2005; Hancock and Sahl 
2006). 
 
1.2 – STRUCTURAL PROPERTIES 
AMPs generally are low molecular weight molecules (2-50 kDa) although some 
of them have a larger size (Brogden, Ackermann et al. 2003). 
According to their secondary structures, AMPs can be classified into the following 
four groups (Boman 1995), (Powers and Hancock 2003): 
 
Group I: linear peptides with α-helical structure [Fig. 1A], such as magainin, 
the cathelicidin LL37 and cecropin (Huang, Huang et al. 2010);   
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Group II: peptides consisting of β-strands connected by one or more 
intramolecular disulfide bridges [Fig. 1B], such as defensins and 
protegrins (Taylor, Barran et al. 2008); 
Group III: linear peptides with an extended structure [Fig. 1C] and a high 
proportion of one or more residues (proline, tryptophan, arginine) 
such as indolicidin and bactenecins (Chan, Prenner et al. 2006); 
Group IV: peptides exhibiting a hairpin-loop structure [Fig. 1D], that is 
interconnected by at least one disulfide bridge. An example is given 
by thanatin (Ma, Niu et al. 2016). 
 
Figure 1 - Representative secondary structures of AMPs [modified by (Jenssen 2009)] 
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1.3 – AMPs: MECHANISM OF ACTION 
The most common AMPs in nature are those with an α-helix or a β-sheet 
conformation (Powers and Hancock 2003) and α-helical peptides are 
among the most studied AMPs to date. Based on their mechanism of 
microbicidal activity, AMPs can be divided into two classes: 
membranolytic peptides and non-membrane active peptides.  
With reference to the first group, the most predominant AMPs have an α-
helical conformation upon interaction with biological membranes (Sato 
and Feix 2006) [Fig. 2].  
 
Figure 2 - Schematic model of the interaction of α-helix AMPs with the cell membrane (modified 
by Huerta-Cantillo 2016) 
 
Looking at the various amino acid sequences of AMPs, their interactions 
with the membrane cannot be predicted: indeed, it depends on a 
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combination of biochemical/biophysical features, including the size, the 
cationicity, the distribution of cationic residues, the amphiphilic character 
and oligomeric state (Hall and Aguilar 2010). However, before reaching 
the target microbial membrane, AMPs interact with the negatively charged 
components of the microbial cell surface, such as LPS, in the outer 
membrane of Gram-negative bacteria, or teichoic acids in the 
peptidoglycan layer of Gram-positive bacteria [Fig. 3]. 
 
 
Figure 3 - Schematic representation of the cell wall of Gram-positive and Gram-negative bacteria 
 
Once reached the periplasmic space, AMPs target the plasma membrane, 
which is rich in anionic lipids and perturb it, following one of these 
mechanisms: 
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x Barrel-stave model, in which AMPs are inserted perpendicularly 
to the plane of the membrane bilayer (Ehrenstein and Lecar 1977), 
forming a pore like a stave (Zhang, Rozek et al. 2001). In this 
structure, the hydrophobic surfaces of the helices interact with the 
fatty acid chains of the membrane phospholipids, while the 
hydrophilic surfaces point inward, producing a transmembrane 
pore. Progressive recruitment of additional peptide monomers 
leads to an increase of the pore size. The leakage of intracellular 
components through these pores subsequently causes cell death 
[Fig. 4A]. It should be noted that a transmembrane pore can be 
formed from as few as three molecules. Therefore, peptides that act 
via the barrel-stave mechanism should kill bacteria about thousand 
fold below the experimentally determined micromolar 
concentrations.  
 
x Toroidal pore model that resembles the “barrel-stave” model. 
However, according to this model, AMPs are always in contact 
with phospholipid head groups [Fig. 4C] (Brogden 2005) of the 
membrane, even when they are perpendicularly inserted into the 
lipid bilayer. The polar faces of the peptides associate with the 
polar head groups of the lipids. The lipids in these openings then 
tilt from the normal position and connect the two leaflets of the 
membrane, forming a continuous bend from the top to the bottom 
in the fashion of a toroidal hole. The pore is lined by both the 
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peptides and the lipid head groups, which are likely to screen and 
mask cationic peptide charges.  
 
x Disordered toroidal pore model in which pore formation is more 
stochastic and involves fewer peptides (Sengupta, Leontiadou et al. 
2008).  
 
x Membrane thinning/thickening affection model, in which the 
thickness of the bilayer can be affected by the presence of the 
peptides, or the membrane itself can be remodeled to form domains 
rich in anionic lipids surrounding the peptide. 
 
x Carpet-like model, in which the peptide molecules line parallel to 
the membrane surface via electrostatic interactions and cover it in 
a “carpet”-like manner [Fig. 4B]. In the second step, the peptides 
reorient themselves such that their hydrophobic face is toward the 
lipids and the hydrophilic face toward the phospholipid head-
groups. After a threshold concentration has been reached, the 
peptides cause membrane permeation, which depends upon the 
properties of a particular peptide. Practically, independently of the 
type of the permeation pathways, which are described as toroidal 
pores or channel aggregates, higher peptide concentrations can lead 
to membrane disintegration (membrane packing collapses into 
fragments with physical disruption of the microbial cell) (Shai 
2002). 
15 
 
 
 
Figure 4 - Schematic representation of some mechanisms of action of membrane-active AMPs: 
barrel-stave model (A), carpet-like model (B) and toroidal-pore model (C). The hydrophobic 
portions of AMPs are in blue, while the hydrophilic ones are in red [From (Bahar and Ren 2013)]. 
 
With reference to the second group (i.e. non-membrane active AMP), the 
mechanism of action of AMPs can involve the inhibition of intracellular 
processes, such as (i) synthesis of nucleic acids; (ii) synthesis of proteins 
or enzymatic activity; (iii) synthesis of the cell wall or microbial septum 
formation (Nguyen, Haney et al. 2011).  
 
 
 
16 
 
 
 
One of the reasons accounting for the preferential activity of AMPs 
towards microbial cells is linked to the anionic nature of microbial 
membranes that are predominantly composed of 
phosphatidylethanolamine (PE) phosphatidylglycerol (PG) and cardiolipin 
(CL), with a high transmembrane potential (-140 mV). In contrast, the 
outer surface of mammalian cell membranes is composed predominantly 
of zwitterionic lipids such as phosphatidylcholine (PC) and 
sphingomyelin, which do not bind strongly to the positively-charged 
AMPs. This hypothesis is supported by in vitro studies on the interaction 
between AMPs and artificial vesicles made of different lipids. These 
studies suggest that the selectivity of AMPs for prokaryotic cells is 
associated to their higher affinity for bacterial membranes compared to 
normal mammalian cell membranes [Fig. 5]. 
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Figure 5 - Molecular basis of cell selectivity of AMPs. AMPs form amphipathic structures with a 
positively charged face (green) and a hydrophobic face (red). Electrostatic interaction between 
the positive charges of AMPs and negatively charged components (yellow) at the eukaryotic cell 
surface (left) and bacterial surface (right) is the major driving force for cellular association. 
 
However, the in vitro interactions between AMPs and membranes are not 
always superimposable to those observed in vivo. An example is given by 
the human cathelicidin AMP LL-37: despite its high affinity for model 
membranes of bacterial-like composition (Neville, Cahuzac et al. 2006),  
its in vivo antimicrobial activity is largely restricted, presumably due to 
physiological conditions (Bowdish, Davidson et al. 2005). 
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1.4 –PHYSICOCHEMICAL PROPERTIES OF ANTIMICROBIAL 
PEPTIDES 
 
The interaction of AMPs with a membrane and their target cell selectivity 
are the result of a combination of multiple physicochemical factors such 
as the AMP’s structure, size, net charge, hydrophobicity and 
amphipathicity (Zelezetsky and Tossi 2006). Changing these properties, 
would help to modify the spectrum of activity of AMPs as well as their 
potency, according to what reported below: 
 
x Length: To form an amphipathic structure with hydrophobic and 
hydrophilic faces, at least 7-8 amino acids are needed. The minimal 
length to span a phospholipid bilayer for α-helical AMPs is about 
20-22 amino acids; however, the peptide’s length can affect the 
AMP’s cytotoxicity. A shorter length is often associated to a lower 
cytotoxicity. Some examples are provided by: (i) a shortened 
version of melittin, the 15-residues-fragment of its C-terminal 
(Subbalakshmi, Nagaraj et al. 1999) and (ii) a shorter derivative of 
HP(2-20), derived from N-terminus of Helicobacter pylori 
Ribosomal protein L1 (RpL1) (Park, Park et al. 2007). Both 
peptides exhibited at least 300-fold lower toxicity to rat and human 
erythrocytes, respectively, compared to their original forms. 
Therefore, AMPs’ length should be taken into consideration when 
designing new synthetic peptides. 
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x  Net charge: AMPs’ net charge is the sum of all positive and 
negative charges of ionizable groups. Cationicity results to be the 
main factor for initial electrostatic interaction with the negatively- 
charged microbial membranes. Altering the net charge, AMPs’ 
activity and cytotoxicity can be changed to achieve a selective 
microbial killing with minimized toxic effects (Jiang, Vasil et al. 
2009). 
 
x Hydrophobicity and amphipathicity: Generally, almost 50% of 
amino acids in the primary structure of natural AMPs are 
hydrophobic. Importantly, an increased hydrophobicity of AMPs 
can increase their cytotoxicity (Dathe, Wieprecht et al. 1997) while 
decreasing their antimicrobial efficacy (Lee, Kim et al. 2002). 
However, a study conducted by Fernandez-Vidal and co-workers 
(Fernandez-Vidal, Jayasinghe et al. 2007) showed that 
amphipathicity is more important than hydrophobicity for the 
binding and permeation of microbial membranes.  
 
x Helicity: The ease of α-helix formation and stability are important 
parameters for the perturbation of biological membranes (Liu, Fang 
et al. 2011). In particular, a reduction in the helical content of a 
peptide has been found to significantly weaken its interaction with 
zwitterionic phospholipid bilayers (Andrushchenko, Vogel et al. 
2007). On the other hand, a stabilized α-helical structure has been 
20 
 
found to enhance the antimicrobial activity of AMPs against Gram-
positive bacteria and fungi (Giangaspero, Sandri et al. 2001). 
 
 
1.5 – FROG-SKIN ANTIMICROBIAL PEPTIDES 
 
Amphibian skin is a rich source of biologically active compounds that are assumed 
to have diverse physiological and defense functions (Conlon 2011).  Frog-skin 
AMPs are synthesized at low metabolic cost by dermal serous glands, which are 
mainly located in the dorsal region of the animal and are controlled by sympathetic 
axons. The cytoplasm of the cells is rich in granules where AMPs are stored, and 
the lumen is reduced to a small empty cavity. Contraction of myocytes 
surrounding the glands, as a reaction to stress or tissue damage, causes a 
synchronous discharge of their content, in a holocrine mechanism (Konig, 
Bininda-Emonds et al. 2015).  
 
A large number of AMPs have been isolated and identified from amphibian 
families belonging to the species Xenopus laevis, Bombina variegata, Bombina 
orientalis, Phyllomedusa bicolor and Phyllomedusa sauvagei and different 
species of Rana (Ladram and Nicolas 2016) [see Tab. 1]. 
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Table 1 - Primary structures of some naturally occurring frog-skin AMPs or their derivatives. 
Peptide Sequence                                                          
Brevinin-1E FLPLLAGLAANFLPKIFCKITRKC 
Brevinin-1Lb FLPMLAGLAASMVPKFVCLITKKC                                                  
Magainin-1 GIGKFLHSAGKFGKAFVGEIMKS 
Magainin-2 GIGKFLHSAKKFGKAFVGEIMNS 
esculentin-1 GIFSKLGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
esculentin-1a GIFSKLAGKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
esculentin-1b GIFSKLAGKKLKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC 
esculentin-C CGIFSKLAGKKLKNLLISGLKNVGKEVGLDVVRTGIDIAGCKIKGECM 
esculentin-2a 
Esc(1-18) 
GILSLVKGVA KLAGKGLAKE GGKFGLELIA CKIAKQC             
 
GIFSKLAGKKLKNLLISG-NH2 
Esc(1-21) GIFSKLAGKKIKNLLISGLKG-NH2 
 
From various Rana genera, many AMPs have been isolated and identified 
with common features and structures. They have been classified into 
several families encompassing brevinin-1, brevinin-2, nigrocin, temporin, 
esculentin-1 and esculentin-2. 
  
 
1.5.1 – The esculentin-1 family  
All members of this family are 46-amino acid residues long and contain 
a C-terminal hepta-membered ring stabilized by a disulfide bridge 
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They have a net charge of +5 at neutral pH and an amphipathic α-
helical structure in membrane mimetic environments (Wang, Zhang et 
al. 2016). Various members belonging to the esculentins-1 family were 
isolated and purified from the cutaneous secretions of Pelophylax 
lessonae/ridibundus (previously classified as Rana esculenta) 
specimen [Fig. 6], using reversed-phase high performance liquid 
chromatography.  
 
 
Figure 6 - A specimen of Pelophylax lessonae/ridibundus 
 
 
 
The antimicrobial activity of these peptides against several microbial 
strains and their hemolytic activity on human erythrocytes are reported 
in [Tab. 2] and expressed as lethal concentration as reported in 
(Simmaco, Mignogna et al. 1993).  
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Table 2 - Antimicrobial and lytic activity of two esculentin peptides. ND= not determined 
 
Strains 
Lethal concentration*(µM) 
Esculentin-1 Esculentin-C 
Escherichia coli D21 0.2 0.2 
Bacillus megaterium Bm11 0.1 0.1 
Staphylococcus Cowan I 0.4 0.4 
Pseudomonas aeruginosa 
ATCC15692 
0.7 1.4 
Candida albicans 0.5 ND 
Red blood cells >100 ND 
*Values taken from (Simmaco, Mignogna, et al. 1993) and (Mangoni, 
Fiocco et al. 2003) 
 
 
Interestingly, a fragment corresponding to the 19-46 portion of 
esculentin peptides was also isolated from skin secretions. 
It was devoid of antimicrobial activity, presumably due to its low net 
positive charge (+1 versus +5 of the whole molecule) at neutral pH 
(Simmaco, Mignogna et al. 1994). Since no antimicrobial activity was 
detected for this fragment, it was then investigated whether this activity 
was retained in the N-terminal portion of the esculentin-1 peptide. The 
1-18 fragment was not found in the HPLC fractionation of the 
secretion, possibly because of its proteolytic degradation. Therefore, 
its antimicrobial activity was analyzed in detail on a synthetic peptide, 
Esc(1-18), amidated at the C-terminus [Tab. 1] to maintain a net charge 
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of +5 at neutral pH and to increase its stability (Mangoni, Fiocco et al. 
2003). Note that the amidation at the carboxyl-end is a very common 
post-translational modification in linear AMPs from frog skin 
(Mangoni, Papo et al. 2006), (Nicolas and El Amri 2009). 
It was found that Esc(1-18) adopted an α-helical structure in lipid 
vesicles mimicking the anionic character of microbial membranes and 
that its antimicrobial activity was comparable to that of the full-length 
peptide (with lethal concentration values ranging from 0.1 to 1.5 μM). 
Furthermore, it showed a lower hemolytic capacity compared to the 
full-length peptide (Mangoni, Fiocco et al. 2003).  
 
Since the minimum length for a peptide in α-helical conformation to 
span a phospholipid bilayer is about 20 amino acids, a longer analog 
containing 21 residues and amidated at its C-terminus, named 
esculentin-1a(1-21)NH2, [Tab. 1, Esc(1-21)], was further synthesized 
and analyzed for its antimicrobial activity. 
 
1.5.2 – Esculentin-1a(1-21)NH2, Esc(1-21) 
Esculentin-1(1-21)NH2, Esc(1-21), shares the first 20 residues with the 
natural esculentin-1a plus a glycinamide at its C-terminus [Tab. 1] (Islas-
Rodriguez, Marcellini et al. 2009). Differently from Esc(1-18), Esc(1-21) 
carries the substitution Leu-11-Ile and three additional C-terminal residues 
(Leu-Lys-Gly) which give it a higher net positive charge at neutral pH 
(+6); an important property for the electrostatic interaction with the 
negatively-charged membranes of microbial cells. 
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It has been demonstrated that Esc(1-21) has a potent antimicrobial 
activity mainly against Gram-negative bacteria, e.g. Pseudomonas 
aeruginosa including both free-living and sessile forms of this 
microbial pathogen (Luca, Stringaro et al. 2013). Esc(1-21) displayed 
the same efficacy against reference and clinical isolates of P. 
aeruginosa with a rapid bactericidal activity (15 min), regardless of 
their multi-drug resistance or mucoid phenotype. This is indicated by 
the similar minimal peptide concentration  which inhibits microbial  
growth (MIC) of these strains (4 µM) as well as by the comparable 
bactericidal concentration causing 99.9% killing of these strains (0.5 
µM or 1 µM) (Luca, Stringaro et al. 2013). In comparison, a weaker 
activity was detected against Gram-positive bacterial strains with MIC 
values ranging from 1 µM to 64 µM (Kolar, Luca et al. 2015).  
Furthermore, Esc(1-21) was found to have the capacity to promote re-
epithelialization of an injured area produced in a monolayer of 
keratinocytes, the most abundant cells in epidermis (Haslam, Roubos 
et al. 2014), at a faster rate than the mammalian AMP LL-37 (Di 
Grazia, Cappiello et al. 2015).  
 
1.6 – PSEUDOMONAS AERUGINOSA 
 P. aeruginosa [Fig. 7] is an opportunistic Gram-negative bacterium 
causing life-threatening infections such as keratitis, pneumonia and burn 
wounds skin infections (Gellatly and Hancock 2013). 
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Figure 7 - Pseudomonas aeruginosa free-living cells 
  
 Its adaptability and high intrinsic antibiotic resistance enable it to survive 
in a wide range of natural and artificial settings, including abiotic and 
biological surfaces. The strengths of this bacterium reside in its high 
production of virulence factors and the ability to form biofilm causing 
direct damage to host tissues or increasing the bacterium competitiveness 
(Streeter, Neuman et al. 2016). P. aeruginosa biofilms [Fig. 8] are bacterial 
communities embedded in a self-produced matrix of extracellular 
polymeric substances, which confer  them a greater resistance to physical 
and chemical factors, including conventional antibiotics, and to immune 
cells, favoring colonization of nearby surfaces [Fig. 8]  (Flemming, 
Wingender et al. 2016). 
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Figure 8 - Pseudomonas aeruginosa biofilm communities 
   
P. aeruginosa infections are often associated with compromised host 
defenses e.g. neutropenia, severe burns or cystic fibrosis (CF) (Lyczak, 
Cannon et al. 2000). In the latter case, P. aeruginosa colonizes the mucus 
present in the airways of CF patients causing persistent and resistant 
bacterial infections that conventional antibiotics cannot eradicate. AMPs 
may represent a breakthrough in the treatment of resistant infections 
because of their non-specific mechanism of action, which involves the 
membrane disruption. 
   
 
1.7 – ANTIMICROBIAL PEPTIDES AS DRUGS: LIMITATIONS AND 
POSSIBLE MODIFICATIONS 
In the last decades, several peptides have entered clinical trials as 
antimicrobial or/and immunomodulatory drugs [e.g. in Tab. 3] (Velden, 
van Iersel et al. 2009), (Paquette, Simpson et al. 2002), (Melo, Dugourd et 
al. 2006), (Nilsson, Janson et al. 2015). 
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Table 3 - Some examples of AMPs tested in clinical studies 
Peptide name Parent name Outcome 
hLF1-11 Lactoferrin established safety in humans  
P-113 Histatins Safety with reduction in gingivitis and 
gingival bleeding 
Omiganan Indolicidin Effective for killing bacteria that live on the 
surface of the skin 
Omiganan Indolicidin Reduced catheter infections 
LL-37 Cathelicidin Approved, no yet recruiting 
Talactoferrin Lactoferrin Completed, no results posted 
 
 
In spite of their important natural roles, several limitations can hinder the 
development of AMPs as therapeutics:  
• Toxicity against mammalian cells at therapeutic dosages;  
• Poor pharmacokinetics due to degradation by proteolytic enzymes; 
• Hampered delivery to the target site at effective concentrations. 
Recent research on AMPs has focused on methods to overcome these 
drawbacks without causing a significant reduction in their antimicrobial 
efficacy (Fjell, Hiss et al. 2012). Amino acid substitution is one of the 
applied strategies for AMP modification. Below is a list of the most 
common approaches to optimize the biological properties of AMPs: 
 
x Modification of AMPs by different natural amino acids: most of these 
studies focus on certain amino acids due to their unique properties. For 
example, proline shows low propensity to form α-helical structures; thus, 
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changes in the proline content may lead to alteration of the peptide 
conformation with a resulting reduction in the cytotoxicity (Zhang, Benz 
et al. 1999). Furthermore, the addition of positively-charged residues into 
the primary structure of AMPs can also reduce the cytotoxicity. An 
example is given by the peptide P60.4, an analog of the human LL-37 with 
two basic residues in substitution of two neutral ones. This analog has been 
successfully used in nasal application against methicillin-resistant 
Staphylococcus aureus (MRSA) (Goblyos, Schimmel et al. 2013). 
 
x Modification of AMPs by amidation: it has been demonstrated that the 
amidation at the carboxyl end of a peptide results in a more stable and 
active AMP, due to the higher cationicity. As shown by Kim et al., the C-
terminal amidation of the AMP PMAP-23 increased by  almost 10-fold the 
peptide cellular uptake, its interaction and perturbation of bacterial 
membranes with respect to the unmodified AMP (Kim, Park et al. 2011). 
 
x Modification of AMPs by non-coded amino acids: this approach is 
widely used in biochemistry to modify native AMPs. For example, the 
incorporation of β-didehydrophenylalanine [Fig. 9] in the primary 
structure of VS1 increases the resistance to proteolytic degradation. β-
didehydrophenylalanine is an unnatural amino acid used to provide better 
folding properties to AMPs (Gupta and Chauhan 2011), (Torino, Mollica 
et al. 2010). 
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Figure 9 - Chemical stucture of β-didehydrophenylalanine residue 
 
Another type of non-natural amino acid mainly used to increase the 
stability of α-helix conformation and presumably the  spectrum of activity 
of AMPs, is the  α-aminoisobutyric acid (Aib) [Fig. 10], (Bellanda, 
Peggion et al. 2001), (De Zotti, Biondi et al. 2012).  
 
 
Figure 10 - Chemical structure of α-aminoisobutyric acid (Aib) residue 
An important strategy that is often used to reduce AMPs cytotoxicity 
without negative effects on the peptide’s functionality is the substitution 
of L-amino acids with the corresponding D-enantiomers. However, D-
amino acids incorporation can also modify the AMPs’ antimicrobial 
activity and selectivity. Furthermore, D-amino acids-containing analogues 
are highly resistant to proteolytic degradation, making AMPs more tolerant 
to proteases (Giuliani and Rinaldi 2011).  
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x Design of hybrid peptides: this is another innovative strategy to enhance 
the spectrum of activity of AMPs and to reduce their hemolytic activity. 
It consists in the fusion of two peptides with antimicrobial activity but 
directed to a different target (Acuna, Picariello et al. 2012). An example 
is given by the HDB2/HDB3-chimera peptide corresponding to the fusion 
of the two different human β-defensin-2 (HDB2) and human β-defensin-
3 (HDB3) that act against different microorganisms. The resulting 
chimera showed the combined antimicrobial activities of the individual 
peptides (Spudy, Sonnichsen et al. 2012).  
 
x Design of antimicrobial peptide conjugates. This novel strategy 
includes the synthesis of stabilized AMPs, AMPs congeners, 
immobilized AMPs and AMP conjugates (Brogden and Brogden 2011). 
In fact, AMPs can be attached/incorporated to/into nano-micro systems 
(e.g. nanoparticles) to improve their biostability, to enhance their 
antimicrobial activity and to reach the infection sites. Engineered 
nanoparticles (NPs) represent an innovation in the field of diagnostics and 
biomedicine. They can be produced with various materials to obtain NPs 
of different size, shape and surface properties suitable for different 
therapeutic approaches (Yih and Al-Fandi 2006).  
In recent years, as for conventional antibiotics, scientific research has 
focused on the realization of AMP-nano conjugates. This is proved by the 
increasing number of scientific reports (Soica, Coricovac et al. 2016) that 
show the use of biodegradable materials, such as poly(lactic-co-glycolic 
acid) (PLGA) [Fig. 11] (Gutjahr, Phelip et al. 2016) or inorganic particles 
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(such as gold or silver) for new therapeutic formulations (Rai, Pinto et al. 
2016), (Ramesh, Grijalva et al. 2016), (Ali, Zafar et al. 2016). 
 
 
Figure 11 - Chemical structure of PLGA 
 
 Encapsulation of drugs into biodegradable NPs is becoming one of the 
innovative strategies for drug delivery, such as the formulation of 
inhalable powder for treatment of lung infections (d'Angelo, Conte et al. 
2014). The encapsulation should serve (i) to protect the drug, i.e. peptide, 
from the action of proteolytic enzymes; (ii) to assist the drug delivery to 
the target site at high concentrations and (iii) to prolong the drug 
residence time in situ, thus sustaining its pharmacological effect and 
reducing the number of administrations (d'Angelo, Conte et al. 2015), 
(d'Angelo, Quaglia et al. 2015). The first two above-mentioned objectives 
can also be achieved by the conjugation of the compound to inorganic 
nanoparticles including those made of gold. Gold nanoparticles (AuNPs) 
are among the most applied nanocarriers in biomedical fields (Pietro, 
Strano et al. 2016) thanks to the interesting elemental properties of gold, 
such as biocompatibility and chemical inertia. Although AuNPs are used 
for the conjugation of several molecules, there is a limited number of 
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studies on the effects of the conjugation of an AMP to them (Rai, Pinto 
et al. 2016). 
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2. Aims of the work 
To optimize the biological properties of AMPs for their development as a 
new therapeutics, three different biochemical approaches were used. 
 
•  Design and synthesis of an analog of Esc(1-21) carrying three Aib 
residues at sequence position 1, 10 and 18  (Huang, Huang et al. 2010)  to 
increase the α-helicity of the peptide and to enlarge its spectrum of activity. 
When inserted into the primary structure of peptides, Aib residues are 
expected to increase the α-helical content of the molecules, due to their 
strong helicogenicity. Importantly, a stabilized α-helical structure is known 
to be a crucial parameter for the AMPs’ activity against Gram-positive 
bacteria (Giangaspero, Sandri et al. 2001) but also to increase their toxicity 
against mammalian cells (Huang, Huang et al. 2010). The Aib-containing 
peptide has been characterized for its structural and biological properties 
and compared with the parent peptide Esc(1-21).  
 
• Design and synthesis of a diastereomer of Esc(1-21), named Esc(1-
21)-1c, by replacing two L-amino acids in the C-terminal portion, i.e. L-
Leu14 and L-Ser17, with the corresponding D-enantiomers. Besides 
making a peptide more resistant to enzymatic digestion, the insertion of D- 
amino acids is expected to disrupt the peptide’s α-helical content (Hong, 
Oh et al. 1999) and to reduce its cytotoxicity. The effect(s) of D-amino 
acids incorporation on the structural/biological properties of the peptide 
have been investigated. 
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• Design and production of two different types of nano-systems to 
protect the AMP from proteolytic degradation and to allow its delivery to 
the target site without altering the antimicrobial properties: (i) inorganic 
gold nanoparticles (AuNPs) coated with Esc(1-21) and (ii) nano-embedded 
microparticles for pulmonary delivery of a model cationic AMP, i.e. 
colistin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
3. Results 
3.1 – THE ANALOG OF Esc(1-21): [Aib1, 10, 18]-Esc(1-21) 
 
3.1.1 - Synthesis of [Aib1, 10, 18]-Esc(1-21) 
An analog of Esc(1-21) containing Aib residues was designed on the basis of the 
following considerations: 
- The Aib residue in position 1 might prevent enzymatic degradation by 
aminopeptidases. It is known that an amidated C-terminus confers protection 
against carboxypeptidases (Rink, Arkema-Meter et al. 2010); therefore, the 
presence of an Aib residue at the C-terminus of Esc(1-21) would not be 
necessary. In comparison, the introduction of Aib residues along the primary 
structure is expected to be potentially beneficial for protection against 
endopeptidases.  
- The α-helix-promoting capabilities of Aib are more effective when it is placed 
internal to the peptide sequence where it can display its influence on 
preceding and following residues in the peptide sequence.  
- In [Fig. 12], the helical wheel plot of the primary structure of Esc(1-21) and 
its analog are shown, where the residues are arranged according to an ideal α-
helical folding. In this conformation, it is possible to identify two faces, one 
hydrophobic and the other one with a more hydrophilic character. It is well 
known that in naturally-occurring Aib-rich peptides of fungal origin, named 
peptaibiotics, Aib residues are located within the hydrophobic face, but also 
at its boundary with the hydrophilic one (Toniolo, Peggion et al. 1994), (De 
Zotti, Biondi et al. 2012).  
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Figure 12 - Helical wheel plots of the primary structure of Esc(1-21) (A) and [Aib1,10,18]-Esc(1-
21) (B).  
 
Following these observations, three Aib residues were placed in the Esc(1-21) 
sequence: two of them as a replacement for the Gly 1 and Gly18, and the third one 
at the boundary between the hydrophobic/hydrophilic faces in substitution for Lys 
10 [Tab. 4].  
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Table 4 – Comparison between the primary structure of Esc(1-21) and Aib1,10,18-analog. Aib 
residues are marked in bold. 
 
3.1.2 - Circular Dichroism  
Far-UV Circular Dichroism (CD) spectra of Esc(1-21) and [Aib1, 10, 18]-Esc(1-21) 
were acquired in collaboration with Dr. Crisma and Dr. Biondi (Institute of 
Biomolecular Chemistry, Padova Unit, CNR). Three different solvents were used: 
water, trifluoroethanol (TFE) and 100 mM sodium-dodecyl sulfate (SDS) aqueous 
solution. In both membrane-mimicking environments, e.g. SDS and TFE, the 
spectra showed two negative maxima near 205 nm and 222 nm and a positive 
maximum at 195 nm [for the figures, please refer to those present in the work 
attached at the end of the manuscript: Biondi B., Casciaro B., di Grazia A., 
Cappiello F., Luca V., Crisma M. and Mangoni ML. “Effects of Aib residues 
insertion on the structural-functional properties of the frog skin derived peptide 
esculentin-1a(1-21)-NH2”. Amino Acids (2016) Oct 11]. This suggested a right-
handed helical conformation for both peptides. Furthermore, the ellipticity ratio 
R=[θ]222/[θ]205 calculated in these environments highlighted a predominant α-
helical conformation for both AMPs (Manning and Woody 1991). Differently, in 
water they adopted a random coil structure.  
Peptide Sequence 
Esc(1-21) H-Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu-Leu-Ile-
Ser-Gly-Leu-Lys-Gly-NH2 
[Aib1, 10, 18]-Esc(1-21) H-Aib-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Aib-Ile-Lys-Asn-Leu-Leu-Ile-
Ser-Aib-Leu-Lys-Gly-NH2 
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However, in TFE/water mixtures of varying composition (20%, 50% and 100%), 
the CD spectra of both peptides showed a significant difference. As indicated in 
Fig. 13, the set of spectra is characterized by an isodichroic point at 203 nm, which 
consists in two-state transition from the disordered conformation in water to the 
α-helical structure in 100% TFE. The helical content of the parent peptide 
increased with increased TFE concentrations (from 20% to 50% and much less 
from 50% to 100%), whereas the Aib1,10,18-analog resulted to be more helical 
already at 20% TFE and the CD spectra slightly changed at higher TFE 
concentrations [Fig. 13]. 
 
 
Figure 13 - Far-UV CD spectra of Esc(1–21) (A) and [Aib1,10,18]-Esc(1–21) (B)  in water (black 
line), 20 % TFE (red line), 50 % TFE (blue line), and 100 % TFE (green line). 
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3.1.3 - Antimicrobial activity 
 The antimicrobial activity of [Aib1,10,18]-Esc(1-21) was tested by the 
microdilution broth assay to determine the MIC against Gram-negative, Gram-
positive bacteria and yeasts. As shown in tab. 5, the MIC values of Esc(1-21) and 
its analog did not show any significant difference against Gram-negative bacteria 
and yeasts. In fact, Esc(1-21) and the analog had the same MICs against almost all 
the strains, with the exception of Escherichia coli ATCC 25922 and Candida 
albicans ATCC 10231 towards which the [Aib1, 10, 18]-Esc(1-21) showed a 2-fold 
lower MIC than Esc(1-21).  
Differently, [Aib1, 10, 18]-Esc(1-21) resulted to be significantly stronger against 
Gram-positive bacteria with respect to the parent peptide. As shown in tab. 5, the 
MICs against Staphylococcus epidermidis strains were 8-fold lower than those of 
Esc(1-21), while the MICs against S. capitis 1 and S. faecalis ATCC 29212 were 
16-fold lower. Furthermore, a 32-fold lower MIC was displayed by [Aib1,10,18]-
Esc(1-21) against S. aureus strain.  
Therefore, the Aib residues replacement was found to be sufficient to confer 
Esc(1-21) a higher activity against Gram-positive bacteria without affecting its 
potency against Gram-negative bacterial strains and yeasts.  
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Table 5 - Antimicrobial activity of Esc(1-21) and [Aib1,10,18]-Esc(1-21) 
 MIC (µM)a 
 
 
Microorganisms 
 
Esc(1-21) 
 
 
[Aib1,10,18]-Esc(1-21) 
Gram-negative bacteria 
  
Acinetobacter baumannii ATCC 19606 2 2 
Escherichia coli ATCC 25922  4 2 
Escherichia coli D21 2 2 
Pseudomonas aeruginosa ATCC 27853 4 4 
Pseudomonas aeruginosa ATCC 19660 8 8 
Yersinia pseudotuberculosis YPIII 1 1 
 
Gram-positive bacteria 
  
Bacillus megaterium Bm11 2 0.5 
Enterococcus faecalis ATCC 29212 >64 8 
Staphylococcus aureus 6938 64 2 
Staphylococcus capitis 1 64 4 
Staphylococcus epidermidis ATCC 12228 16 2 
Staphylococcus epidermidis 21 16 2 
Staphylococcus hominis 1 1 1 
 
Yeasts 
  
Candida albicans ATCC 10231 4 2 
Candida guillier mondii 1 1 
a Values are those obtained from at least three readings out of four independent measurements  
 
3.1.4 - Cytotoxicity on mammalian cells 
The cytotoxicity of Esc(1-21) and its analog was evaluated by the 3(4,5-
dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide (MTT) assay on two 
different types of mammalian cell lines: the human keratinocytes (HaCaT) cells 
and the human alveolar lung epithelial (A549 cells) after 24 h treatment.  
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Figure 14 - Peptides’ effect on the viability of A549 cells (A) or HaCaT cells(B). About 4x104 cells 
were plated in each well of a microtiter plate in culture medium. After overnight incubation, the 
medium was replaced with 100 µl fresh medium supplemented with the peptides at different 
concentrations. After 24 h of peptide treatment, cell viability was determined by the MTT reduction 
to insoluble formazan. Cell viability is expressed as percentage with respect to the control (cells 
not treated with the peptide). Data points represent the mean of triplicate samples ± SEM. The 
levels of statistical significance between the two peptides are: ***p < 0.001; ****p < 0.0001 
 
As reported in Fig. 14, no significant differences were found when the two 
peptides were assayed against both cell lines at low concentrations (i.e. 2 and 4 
µM). 
Nevertheless, when the analogue was tested at higher concentrations, i.e. 32 and 
64 µM, cell viability sharply decreased. This is in line with the higher content of 
α-helicity in the Aib-containing peptide, which is known to be critical for 
mammalian cell lysis (Gazit, Lee et al. 1994).   
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3.2 – THE ANALOG OF Esc(1-21): Esc(1-21)-1c 
 
3.2.1 - Synthesis of Esc(1-21)-1c 
With the aim to protect Esc(1-21) from proteolytic degradation and to reduce its 
toxicity against mammalian cells, an analogue named Esc(1-21)-1c was designed 
by replacing two L-amino acids with the corresponding D-amino acid enantiomers 
(L-Leu14 ÆD-Leu14; L-Ser17ÆD-Ser17) [Tab. 6]. 
  
Table 6 - Primary structure of Esc(1-21) and Esc(1-21)-1c. D-amino acids are in italics.  
 
The diastereomer Esc(1-21)-1c was rationally designed on the bases of the 
following considerations:  
- Several studies indicated that the reduction of α-helical content of a 
peptide correlated with its reduced ability in perturbing mammalian 
membranes causing cell lysis (Shai and Oren 1996), (Strahilevitz, Mor et 
al. 1994).  
- D-amino acids are known to be D-helix breakers (Grieco, Carotenuto et 
al. 2013). Previous work performed with the shorter analog of Esc(1-21), 
[Esc(1-18)], indicated that the C-terminal half of  this latter adopted an  α-
helical conformation in a hydrophobic environment mimicking the 
electrically neutral membranes of mammalian cells.  Note that Esc(1-18) 
Peptide Sequence 
Esc(1-21) Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu-Leu-Ile-Ser-
Gly-Leu-Lys-Gly-NH2 
Esc(1-21)-1c Gly-Ile-Phe-Ser-Lys-Leu-Ala-Gly-Lys-Lys-Ile-Lys-Asn-Leu-Leu-Ile-Ser-
Gly-Leu-Lys-Gly-NH2 
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differs from Esc(1-21) by a single amino acid in position 11 and lacks the 
C-terminal three residues tail. Since this tail contains two achiral glycine 
residues at positions 18 and 21, it is very unlikely that this region of Esc(1-
21) folds in a stable helical conformation. On the contrary, replacement of 
two L-amino acids at positions 14 and 17 with the corresponding D-
enantiomers would break the first turn of the D-helix expected to be 
present in the C-terminal half of Esc(1-21). 
3.2.2 – Peptide stability in human serum 
Biostability of both peptides was examined in the presence of 10% or 30% fresh 
human serum after 5 h and 24 h incubation at 37 °C in collaboration with Prof. 
Pini (Department of Medical Biotechnology, University of Siena). The data 
showed that the diastereomer Esc(1-21)-1c was more stable than the all-L Esc(1-
21). As determined by HPLC (Tab. 7, refer to Fig. 15), the amount of non-
degraded peptide was ~46% and 25% after 24 h incubation with 10% or 30% 
serum, respectively. The corresponding amount of Esc(1-21) was only ~22% and 
11.5% [Tab. 7]. 
 
Table 7 - Peptide amount (%) after 5 h and 24 h incubation with human fresh serum at 37 °C 
Peptide amount (%)a 
5 h 24 h 
Peptide 10% serum 30% serum 10% serum 30% serum 
Esc(1-21) 
 
44.4 
 
20.95 
 
22.19 
 
11.5 
Esc(1-21)-1c 
 
63.34 
 
30.12 
 
45.61 
 
25.46 
aPeptide amounts were determined by the peak areas of the RP-HPLC relative to those of the 
control peptides (dissolved in PBS) at 0 min (set as 100 %) as demonstrated in Fig. 15. 
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Figure 15 - RP-HPLC profile of Esc(1-21) (A) and Esc(1-21)-1c (B) after 5 h [violet line] and 24 
h [red line] incubation with 30% fresh human serum at 37 °C. The black line indicates the crude 
peptide dissolved in PBS (control, Ctrl).  Percentages of peptide amount are also indicated. As 
explained in the legend to Table 7, they were determined by the peak areas at 28 or 26 minutes 
compared to the corresponding control peptide (Ctrl) 
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3.2.3 - Structural properties  
The secondary structure of both peptides was characterized by CD spectroscopy 
in the lab of Prof. Bhunia (Department of Biophysics, Bose Institute, India). The 
conformations adopted by Esc(1-21) and Esc(1-21)-1c were determined in: 
aqueous solution, SDS (a surfactant that mimics the anionic nature of bacterial 
membrane) and dodecylphosphocholine, DPC, (to mimic the zwitterionic nature 
of mammalian plasma membranes) [Fig. 16]. 
 
Figure 16 - CD spectra of Esc(1–21) (A)  and Esc(1–21)-1c (B)  in aqueous solution [black line], 
40 mM SDS [blue line] and 10 mM DPC [red line]. 
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In aqueous solution, the two peptides assumed a random-coil conformation. 
Differently, in DPC or SDS, both isomers adopted an α-helix conformation with 
higher helical propensity for Esc(1-21) compared to the diastereomer. The 
percentages of D-helix of the peptides in the three different environments are 
reported in [Tab. 8]. 
Table 8 - Percentage of α-helix content in the secondary structure of Esc(1-21) and Esc(1-21)-1c 
in aqueous solution, SDS and DPC. 
 
Helix content (%) 
Environment Esc(1-21) Esc(1-21)-1c 
Aqueous solution 6 4 
SDS 47 24 
DPC 26 12 
 
As expected, these results indicated a remarkable loss of α-helicity in the 
diastereomer, due to the incorporation of D-amino acids that break the α-helical 
structure. This effect was more pronounced in DPC and was also confirmed by 
NMR studies (performed in the laboratory of Prof. Bhunia). They revealed a 
flexible C-terminal arm in Esc(1-21)-1c compared to the all-L peptide [Fig. 17]. 
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Figure 17 - Three dimensional solution structures of Esc(1-21) (A) and Esc(1-21) (B)  in DPC 
micelles. The cartoons represent the side chain orientation of a representative NMR structure of 
both peptides bound to DPC. These images were produced using the PyMOL software.     
 
 
3.2.4 - Antibacterial activity  
The antimicrobial activity of Esc(1-21) and its diastereomer was tested against 
several strains of P. aeruginosa (either reference or clinical isolates from CF 
patients) in phosphate buffered saline (PBS). As shown in fig. 18, Esc (1-21) was 
able to cause about 99.9 % of P. aeruginosa strains within 30 min at a 
concentration of 1 PM. A weaker bactericidal activity was observed for the 
diastereomer Esc (1-21)-1c, being necessary a peptide concentration 4-fold higher 
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in order to achieve the same effect as that induced by the all-L parent peptide. 
However, at the same concentration used for the Esc(1-21) (1 PM) the 
diastereomer was capable of exerting a pronounced microbicidal activity causing 
approximately 90% killing of the bacterial population (dotted line in Fig. 18).  
 
Figure 18 – Antibacterial activity of Esc(1-21) and Esc(1-21)-1c against some P. aeruginosa 
strains after 30 min treatment. The results are the average of three different experiments ± SEM. 
Broken line represents 90% of killing. The levels of statistical significance between the two 
peptides are: *p < 0.05 (Student test). 
 
Remarkably, when the two peptides were tested against the sessile form of these 
strains, the diastereomer had a higher anti-biofilm activity than the all-L peptide 
on the clinical isolates AA11 and TR1, causing 95% killing of viable biofilm cells 
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at 12.5 µM compared to 25 µM of Esc(1-21) [please refer to the work attached at 
the end of the manuscript: “D-Amino acids incorporation in the frog skin-derived 
peptide esculentin-1a(1-21)NH2 is beneficial for its multiple functions.” By Di 
Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, 
Mangoni ML]. 
 
3.2.5 - Mode of action 
 
3.2.5.1 - Membrane perturbation assay on bacterial cells 
 
In order to investigate whether the diastereomer had a membrane perturbing 
activity on Pseudomonas cells, as already demonstrated for Esc(1-21) (Luca, 
Stringaro et al. 2013), the release of large intracellular compounds, such as the 
cytoplasmic β-galactosidase, from peptide-treated cells, was assessed. For this 
purpose, a recombinant P. aeruginosa strain constitutively expressing this enzyme 
was used (see Materials and Methods). Esc(1-21) provoked ~58 and 66% enzyme 
leakage at those concentrations (10 and 20 μM) causing the complete microbial 
death. A slight weaker damage was found for the diastereomer, as demonstrated 
by the minor leakage of β-galactosidase (~ 49 and 62 % at 10 and 20 µM, 
respectively) at the same peptide concentrations causing ~100% microbial killing. 
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3.2.5.2 - Membrane perturbation assay on lipid vesicles 
 
To investigate whether the membrane perturbing activity of the peptides was not 
a stereospecific mechanism mediated by recognition of chiral targets, e.g. proteins, 
carboxyfluorescein (CF)-loaded liposomes were used. The membrane 
permeability can be tested by entrapping a fluorescent molecule, i.e. CF, in the 
water volume inside the lipid vesicles at high concentration. This induces self-
association and quenching of the dye (Stella, Mazzuca et al. 2004). After peptide 
addition, the membrane perturbation leads to probe release and dissociation with 
a resulting fluorescence increase.  
Both peptides were tested at different concentrations on PE/PG liposomes (7:3 v:v, 
200 µM), which mimic the lipid composition of the anionic membrane of Gram-
negative bacteria. As shown in Fig. 19, Esc(1-21) showed a stronger membrane 
perturbing activity compared to the diastereomer,  as indicated by the higher 
fluorescence values obtained 30 min after peptide addition to the lipid vesicles.  
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Figure 19 - Fluorescence intensity after 30 min from the addition of both peptides to PE/PG 
liposomes (7:3, v:v). Control (Ctrl) is given by lipid vesicles not treated with the peptide. Data 
points represent the mean of triplicate samples ± SD. The levels of statistical significance between 
the two peptides are: *p < 0.05 
 
This is in agreement with the results of the β-galactosidase assay and the higher 
activity of Esc(1-21) against the free-living  form of P. aeruginosa compared to 
the diastereomer. In addition, it can be excluded that a stereospecific interaction 
with a membrane receptor is involved in the mechanism of membrane perturbation 
of both peptides.  
 
3.2.6 - Cytotoxicity on mammalian cell lines 
 
The effect of the two peptides on the viability of two different cell lines was 
analyzed by the MTT assay. In particular, the cytotoxic effect of both Esc(1-21) 
and Esc(1-21)-1c was tested on A549 cells and mammalian macrophages Raw 
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264.7 after 24 h treatment with different peptide concentrations. Esc(1-21)-1c 
resulted to be less toxic than the parent peptide at the highest concentrations used 
against both types of cells. This is presumably due to its lower α-helical content 
compared to Esc(1-21). [For the figures, please refer to those present in the work 
attached at the end of the manuscript: “D-Amino acids incorporation in the frog 
skin-derived peptide esculentin-1a(1-21)NH2 is beneficial for its multiple 
functions.” By Di Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, 
Di YP, Shai Y, Mangoni ML].  
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3.3 – PEPTIDE CONJUGATION TO NANOPARTICLES: 
AuNPs@Esc(1-21) 
 
3.3.1 - Synthesis of AuNPs@Esc(1-21) 
AuNPs were synthetized by citrate reduction of gold and found to have an average 
size of ~ 14 nm [Fig. 20].  
 
 
Figure 20 – Transmission electron microscopy (TEM) analysis of AuNPs. A small volume of 
AuNPs was dropped onto a TEM grid and after drying, was imaged using a TEM Tecnai F20. 
AuNPs as synthesized (A). AuNPs@PEG (B). AuNPs@Esc(1-21) (C). Scale bar: 20 nm. 
 
As shown in fig. 20, AuNPs preserved the same size and spherical shape in every 
step of their synthesis. With the aim to increase their stability, a bifunctional 
poly(ethylene glycol) (PEG) bearing a thiol and a carboxylic group was used [SH-
EG(8)-(CH2)2-COOH]. The two reactive groups are important for the 
functionalization of AuNPs: the PEG was attached to the AuNPs via a gold-thiol 
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bond (AuNPs@PEG); while the carboxylic group was used for further 
derivatization with the peptide via carbodiimide-mediated coupling.  
The carboxylic groups of the AuNPs@PEG were activated with different amounts 
and ratios of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS) and the stability of the nanoparticles was 
assessed by UV-Vis spectroscopy, measuring the absorbance of the maximum 
peak at 519 nm and the absorbance at 600 nm  (Ivanov, Bednar et al. 2009). For 
stable AuNPs, the ratio between absorbance value at 519 and 600 nm should be 
higher than 4, while for aggregated NPs the ratio decreases. As the NPs stability 
depends on a delicate balance between charges, with the aim to optimize the 
covalent linkage of the peptide, four different conditions were assayed [Tab. 9]. 
The addition of three different ratios and amounts of EDC:sulfo-NHS led to a 
slight aggregation of the AuNPs@PEG, as shown by the UV-Vis spectra and the 
resulting absorbance ratio [Fig 21A,B,C]. In comparison, as indicated in [Fig. 
21D], the activation with 2.5 Pmol of EDC and 4.6 Pmol of sulfo-NHS maintained 
the stability of AuNPs@PEG.  For this reason, this ratio was selected for the 
addition of the peptide.  
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Table 9 - Amounts of EDC and sulfo-NHS used for activation of AuNPs@PEG and corresponding 
stability condition (i.e. aggregation or non-aggregation) 
 
Condition EDC  
(Pmol) 
Sulfo-NHS 
(Pmol) 
Aggregation? 
1 10 18.4    Yes 
2 2,5 9,2 Yes 
3 5 8,4 Yes 
4 2.5 4,6 No 
 
 
Figure 21 - UV−Vis spectroscopy of the AuNPs@PEG without EDC and sulfo_NHS (blue line) 
and the same NPs activated using the conditions indicated in table 11 (red line). To assess the 
stability of the AuNPs@PEG, the ratio 519/600 nm was calculated. Only using condition number 
4 the AuNPs@PEG remained stable. 
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After activation, different amounts of Esc(1-21) ranging from 1.5 Pg to 4 Pg were 
added to the same quantity of AuNPs@PEG. As shown by UV-spectra, the 
addition of 3 Pg [Fig. 22C] and 4 Pg [Fig. 22D] led to aggregated nanoparticles 
(absorbance ratio 519/600 nm lower than 4). The addition of 1.5Pg and 2Pg [Fig 
22A, B] maintained AuNPs@PEG stability. Therefore, 2 µg of Esc(1-21) were 
used as an optimal amount for the functionalization without causing precipitation 
of the negatively-charged AuNPs@PEG during the coupling process. 
 
Figure 22 - UV−Vis spectroscopy of the AuNPs@PEG (blue line) obtained from condition 4 (Tab. 
11) compared to AuNPs@Esc(1-21) (red line) obtained after conjugation of AuNPs@PEG with a 
different amount of peptide: 1.5 µg (A); 2 µg (B); 3 µg (C); 4 µg (D). 
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As indicated in the experimental section, the amount of peptide in the supernatant 
(not attached to the AuNPs@PEG) was then quantified. By knowing the amount 
of peptide added to the sample for functionalization, it was possible to determine 
by difference the amount of peptide bound to the AuNPs@PEG: 0.7 Pg of peptide 
resulted to be conjugated to 20 pmol of AuNPs@PEG, resulting in about 16 
molecules of peptide per AuNP@PEG. The comparison between the molar 
concentration of AuNPs@Esc(1-21) and the corresponding molar concentration 
of peptide coated onto AuNPs@PEG is shown in [Tab. 10]. 
Table 10 - Comparison between molar concentration of AuNPs@Esc(1-21) and the 
corresponding molar concentration of Esc(1-21). 
Molar concentration of 
AuNPs@Esc(1-21) 
Molar concentration of peptide 
coated onto AuNPs@Esc(1-21) 
20 nM 0.35 µM 
10 nM 0.17 µM 
5 nM 0.08 µM 
 
3.3.2 - Antipseudomonal activity  
The free Esc(1-21) was tested against a high bacterial cell density i.e. 4 x 108  
CFU/mL (which was needed to prepare samples for the electron microscopy) and 
found to provoke 50% killing of the planktonic form of P. aeruginosa within 20 
minutes at 1 µM (MBC50, minimal bactericidal concentration causing at least 50% 
of bacterial death). However, when the peptide was coated onto AuNPs@PEG, it 
was more active with a MBC50 ~ 12 fold lower than that of the free form (0.08 
µM, Tab. 11). Interestingly, AuNPs@Esc(1-21) were found to have a significantly 
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higher activity also against the biofilm form of P. aeruginosa with a minimal 
bactericidal concentration causing at least 50% of eradication of biofilm 
(MBEC50,) ~ 17 fold lower than that of the free peptide within 2 h of treatment. 
Importantly, no lethal activity was displayed by AuNPs@PEG against both forms 
of P. aeruginosa. 
 
Table 11 - Antimicrobial activity of Esc(1-21) and AuNPs@Esc(1-21) on both free living and 
biofilm forms of P. aeruginosa ATCC 27853 
 Antibacterial Activity 
 
Compound 
Planktonic form  
MBC50 
Biofilm form 
MBEC50 
Esc(1-21) 1 PM 3 µM 
AuNPs@Esc(1-21) 5 nM (=0.08 PM peptide) 10 nM (=0.17 PM peptide) 
 
3.3.3 - Mechanism of antipseudomonal activity 
To investigate whether the conjugation to AuNPs affected the membrane-
perturbing activity of Esc(1-21), the Sytox Green assay was performed [Fig. 23]. 
Sytox Green is a membrane-impermeable probe whose fluorescence intensity 
enhances upon binding to DNA, once it has entered cells with a perturbed 
cytoplasmic membrane. When AuNPs@Esc(1-21) were used at 10 nM, a 
concentration causing approximately 70% bacterial death of the planktonic form 
(data not shown), a fast increase of fluorescence intensity was noted after their 
addition to the bacteria. This suggests that a higher membrane damage was 
induced by AuNPs@Esc(1-21) with respect to the same amount of free peptide. 
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Figure 23 - Kinetics of cytoplasmic membrane permeabilization of P. aeruginosa ATCC 27853 (4 
x 108 CFU/ml) induced by 10 nM AuNPs@Esc(1-21) or the corresponding concentration of free 
Esc(1-21). Once basal fluorescence reached a constant value, 10 nM AuNPs@Esc(1-21) or 
AuNPs@PEG as well as the equivalent concentration of free  Esc(1-21) were added, and changes 
in fluorescence (λexc= 485 nm, λ ems = 535 nm) were monitored for 30 min. Control (Ctrl) was given 
by buffer-treated bacteria. The ratio of each value to the initial one measured after 1 min from 
NPs/peptide addition is reported on the y-axis. The values represent the mean of triplicate samples 
from a single experiment, representative of three different experiments. 
 
The effect of the membrane-perturbing activity of AuNPs@Esc(1-21) at their 
MBC50 was also visualized by electron microscopy. The planktonic form of P. 
aeruginosa ATCC 27853 was treated with AuNPs@Esc(1-21) and AuNPs@PEG 
at different incubation times. As visualized by scanning electron microscopy 
(SEM) [Fig. 24], AuNPs@Esc(1-21) appeared to be located on the microbial 
surface already after 1 min incubation with bacteria compared to the control 
sample and to the AuNPs@PEG-treated bacteria. After 8 min treatment, 
AuNPs@Esc(1-21) formed clusters around the cells at various points and caused 
membrane disruptions, with leakage of intracellular material [Fig. 24, arrows]. 
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Figure 24 - SEM images of P. aeruginosa ATCC 27853 cells after 1 min (left panels) or 8 min 
(right panels) treatment with AuNPs@Esc(1-21) at the MBC50 or with AuNPs@PEG, at the same 
molar concentration. Controls (Ctrl) were buffer-treated cells. Insets are magnifications of image 
areas indicated by the black frame. Arrows indicate cell debris. 
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This outcome became more pronounced after 15 min treatment with a drastic 
change in the bacterial shape and a marked disintegration of the cellular structure, 
as shown by TEM [Fig. 25].  
 
 
Figure 25 - TEM micrographs of P. aeruginosa cells after 15 min treatment with AuNPs@Esc(1-
21) at the MBC50 (A) or buffer (B).  Black arrows indicate lysed bacterial cells. Scale bar: 200 nm 
 
A schematic representation of AuNPs@Esc(1-21) and their effect on P. 
aeruginosa is reported in [Fig. 26].  
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Figure 26 - Schematic representation of the synthesized AuNPs@Esc(1-21) and their damage 
caused on P. aeruginosa cells. 
 
3.3.4 - Antipseudomonal activity after pre-treatment with a proteolytic 
enzyme 
 
AuNPs@Esc(1-21) were found to retain their antipseudomonal activity after pre-
treatment with a proteolytic enzyme, e.g. trypsin. In fact, when both the free 
peptide and the conjugated AuNPs@Esc(1-21) (at their MBC50) were pre-treated 
with trypsin, only ~ 13% of bacterial killing was obtained for the free peptide 
(about 4-fold reduction of activity). On the contrary, no significant change in 
killing activity was manifested by AuNPs@Esc(1-21) after incubation with 
trypsin [Fig. 27]. This is likely due to the higher resistance of Esc(1-21) to 
proteolytic degradation upon its coating to AuNPs@PEG.  
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Figure 27 - Antipseudomonal activity of Esc(1-21) or AuNPs@Esc(1-21) at their MBC50 (1 µM 
and 5 nM, respectively) after treatment with trypsin (0.02 µg/mL). The percentage of bacterial 
killing was calculated compared to the control (buffer-treated bacterial cells) and is reported on 
the y-axis. Dotted line indicates 50% bacterial killing. Data points are the mean of triplicate 
samples ± SEM of three independent experiments.   
 
3.3.5 – Cytotoxicity on human keratinocytes  
Both AuNPs@Esc(1-21) and AuNPs@PEG were tested for their cytotoxicity on 
human cells, i.e. keratinocytes (HaCaT cells) by the MTT assay. According to 
published papers showing harmless effects of AuNPs (Chatterjee, Bandyopadhyay 
et al. 2011) or Esc(1-21) (Di Grazia, Cappiello et al. 2015), both NPs showed 
negligible toxicity.  In particular, both peptide-coated and non-coated NPs were 
unable to reduce the number of metabolically active cells within 2 h [Fig. 28] and 
24 h treatment up to the highest concentration used (e.g. 60 nM, which corresponds 
to 12 x MBC50).  
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Figure 28 - Effects of AuNPs@PEG or AuNPs@Esc(1-21) on the viability of HaCaT cells after 2 
h treatment. Cell viability was determined by the MTT reduction to insoluble formazan. The 
percentage represents the cell viability with respect to the control. Data points are the mean of 
triplicate samples ± SEM of three independent experiments. 
 
3.3.6 - Pseudo-wound healing activity on a keratinocytes monolayer 
As reported in the literature (Di Grazia, Cappiello et al. 2015), Esc(1-21) has been 
found to have the capability to stimulate in vitro the migration of mammalian cells, 
e.g. keratinocytes and bronchial epithelial cells. To verify whether the conjugation 
to AuNPs affected the AMP’s ability to promote migration of keratinocytes, a 
pseudo-wound healing assay was carried out by means of special cell culture 
inserts (see Materials and Methods). As shown in Fig. 29, AuNPs@Esc(1-21) 
were able to retain the ability of the peptide to induce re-epithelialization by 
migrating HaCaT cells. The functionalized NPs promoted the closure of the 
pseudo-wound in the HaCaT monolayer within 9 h and with a similar rate to that 
displayed by a 3-fold higher concentration of free Esc(1-21), i.e. 0.25 µM. 
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Figure 29 - Effect of AuNPs@PEG, Esc(1-21) and AuNPs@Esc(1-21) on the closure of a pseudo-
wound field produced in a monolayer of HaCaT cells, seeded in each side of an ibidi culture insert. 
(A): Cells were grown to confluence and afterwards, they were treated with 5 nM AuNPs@PEG, 
AuNPs@Esc(1-21) or with 0.25 µM Esc(1-21). Cells were photographed at the time of insert 
removal (0 h), examined for cell migration after 3, 6 and 9 h, and compared to the control (Ctrl.) 
All data are the mean of three independent experiments ± SEM. The levels of statistical significance 
between Ctrl and treated samples are indicated as follows *p < 0.05, **p < 0.01. (B): Micrographs 
showing representative results of pseudo-“wound” closure after 6 h treatment. 
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3.4 – ENGINEERED NANOPARTICLES FOR THE LOCAL 
DELIVERY OF A CATIONIC AMP 
 
Another important strategy to allow AMPs to efficiently cross biological barriers 
(e.g. the lung mucus and the extracellular matrix of biofilm communities) before 
reaching the target infectious site and to prolong their therapeutic effect is given 
by the design of appropriate nano-embedded microparticles (NEM). Using colistin 
(Col, Fig. 30) as a model cationic AMP, inhalable dry powders consisting in 
biocompatible and biodegradable synthetic polymers (i.e. PLGA) loaded with 
colistin and included in micrometric inert carriers (e.g. lactose, mannitol), already 
employed in inhaled medicines, were developed. Col is the only AMP currently 
used for treatment of lung infections in CF patients (Uttley, Harnan et al. 2013). 
However, its poor lung bioavailability and elevated therapeutic dosage (160 mg 
twice a day delivered by nebulization of a Col solution) make it a drug of last 
resort for treatment of bacterial infections. 
 
Figure 30 - Chemical structure of colistin 
 
68 
 
The aforementioned formulations should: (i) land in the lungs; (ii) deliver AMP-
loaded NPs upon dissolution of the inert carrier; (iii) shield AMP interactions with 
mucus/biofilm promoting drug availability to bacteria; (iv) prolong drug release 
and allow the establishment of higher drug gradients in the mucus layer. 
 
3.4.1 - Synthesis and Properties of colistin-loaded nanoparticles 
Thanks to the expertise of Dr. d’Angelo (University “Federico II”, Naples, 
Italy) Col-loaded nanoparticles (NPs) made of PLGA were produced by 
emulsion/solvent diffusion technique in the presence of chitosan (CS) or 
poly(vinyl alcohol) (PVA). Both CS-modified and PVA-modified NPs 
resulted to have a diameter of 300 nm; a spherical core-shell structure, as 
shown by TEM images [Fig. 31] and a similar Col entrapment efficiency 
(63 ± 1 % and 60 ± 2 % for Col-CS and Col-PVA NPs, respectively). 
Nevertheless, a difference on NPs zeta potential was observed (+12.4 ± 2.1 
and -7.1 ± 1.4 for Col-CS and Col-PVA NPs, respectively), likely 
attributed to the presence of CS or PVA on particle surface.   
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Figure 31 - Schematic representation of the Col-loaded PLGA-based NPs and the corresponding 
TEM images 
The two formulations also were observed to have a different in vitro kinetic of 
Col-release. In Fig. 32 the percentages of Col released over time at physiological 
condition (pH 7.2 and 37° C) are reported: CS-NPs showed a more rapid kinetic 
in the first hours of incubation with respect to the PVA-modified NPs. Indeed, 
while 50% of Col was released within 6 hours from CS-NPs, no more than 5% 
was released from PVA-NPs. However, after an initial burst, both formulations 
sustained Col release for approximately 15 days.  
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Figure 32 - Release profiles of Col in PBS at pH 7.2 and 37 °C for both formulations: Col-CS in 
green and Col-PVA in blue. Experiments were done in triplicate for each time point of release 
kinetics and the results are expressed as percentage of Col released from NPs ± SD over time  
(n = 6). 
The interactions between NPs and mucin appears to be crucial for an efficient 
penetration across the pulmonary mucus layer. The transport of Col-loaded NPs 
through artificial CF mucus was determined using a Transwell-multiplate assay. 
The stronger interaction of CS-modified NPs, with respect to PVA-NPs, led to a 
faster diffusion of NPs across the artificial mucus layer. Indeed, as reported in 
[Fig. 33B] more than 70% of the initial CS-NPs passed through the mucus layer 
in the first 6 hours, while for PVA-NPs only 40% of the initial amount was found 
in the acceptor compartment of the transwell plate. When the free Col was tested 
in the same assay, it was not able to diffuse through the mucus up to 24 hours.  
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Figure 33 - Transport of Col-loaded NPs through artificial CF mucus as determined by the 
Transwell multiplate assay. Schematic representation of the experimental set-up (A); percentage 
amount of Col-loaded NPs permeated across the artificial mucus layer as a function of time (B). 
Data are mean ± SD of values calculated on three different batches (n = 6). 
3.4.2 – Properties of colistin-loaded NEM  
The surface-engineered NPs (CS and PVA-modified) were embedded into 
microparticles in order to produce NP-based dry powders for the delivery of Col 
in the respiratory tract and lung. The microparticles were produced using an inert 
carrier (i.e. lactose) through an optimized spray-drying process. As indicated by 
SEM analysis [Fig. 34], the obtained NEM (Col-CS_L and Col-PVA_L) resulted 
to be spherical with a geometric diameter ranging from 6.4 µm to 8.3 µm. The 
formulations were characterized for their in vitro aerosolization properties to 
evaluate if the spray-drying process with lactose could interfere with the NPs 
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properties: both size and ζ-potential of Col-CS and Col-PVA NPs remained 
unchanged after the process (data not shown).    
 
Figure 34 - SEM images of optimized lactose microparticles embedding engineered PLGA NPs: 
Col-CS_L NEM (left) and Col-PVA_L NEM (right) 
3.4.3 - In vitro activity on P. aeruginosa biofilm 
The antimicrobial activity against P. aeruginosa biofilm was tested on the 
reference strain of P. aeruginosa ATCC 27853. The ability of the free Col and the 
two NEM formulations to eradicate biofilm was evaluated at different incubation 
times (24, 48 and 72 h). As expected, the free Col was able to eradicate 90% of 
biofilm biomass within the first 24 h, but this effect was significantly diminished 
after 48 h and completely lost after 72 h. In comparison, the Col-loaded NEMs 
showed a different anti-biofilm activity: despite a weaker biomass reduction (~ 
50%) was found during the first 24 h of treatment at 7.5 and 15 µg/ml, this activity 
was preserved for 72 h. More precisely, this effect was retained for 72 h by the 
Col-PVA, while the anti-biofilm activity of Col-CS NEMs resulted to be less 
pronounced at the last time point. This outcome may be due to the different kinetic 
of Col release from the two NEMs [Fig. 35]. 
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Figure 35 - Percentage of P. aeruginosa ATCC 27853 biofilm biomass after 24 h, 48 h and 72 h 
treatment with free Col (A), Col-PVA_L NEM (B) and Col-CS_L NEM (C) compared to the control 
sample (100% biofilm biomass, red broken line). All data are the mean of at least three 
independent experiments ± SEM. The level of statistical significance between groups was 
calculated by the Student’s t test and is indicated as follows: *, p < 0.05; 
**p < 0.01;***, p < 0.001. 
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3.4.4 - Penetration of fluorescent NPs inside P. aeruginosa biofilm 
Confocal microscopy analysis was performed to verify the ability of Col-loaded 
formulations to penetrate inside P. aeruginosa biofilm. In Fig. 36, P. aeruginosa 
ATCC 27853 biofilm treated for 24 h with NEM incorporating fluorescent NPs is 
shown. The red color indicates the distribution of rhodamine-labeled NPs while 
the green fluorescence shows the SYTO®-9-labeled biofilm bacteria. In 
particular, the higher green fluorescence intensity observed in some points may 
represent the intracellular DNA released by damaged cells and to which SYTO®-
9 strongly binds.  
 
Figure 36 - Confocal analysis of preformed P. aeruginosa ATCC 27853 biofilm after 24 h 
treatment with fluorescent Col-CS_L or Col-PVA_L NEM at 3.8 μg/ml Col concentration. Biofilm 
cells were stained and visualized using SYTO®-9, while rhodamine-labeled NPs were used to 
produce Col-loaded NEM. Each panel shows reconstructions from the top in the large panel and 
sides in the right and bottom panels (xy, yz, and xz dimensions). Three-dimensional 
reconstructions of biofilms are shown on the far right panel (3D image). 
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4. Discussion 
Microbial infections currently cause millions of deaths every year and the growing 
emergence of microorganisms resistant to the available drugs has become a 
worldwide problem for human health. With the onset of antibiotic resistant strains, 
new molecules able to eradicate bacterial infections are urgently needed. AMPs 
hold promise for the development of new anti-infective agents and the scientific 
research is focusing on their discovery and characterization. AMPs show different 
mechanisms of action, but most of them have a membrane-perturbing activity on 
microbial cells. This non-specific mode of action very rarely leads to microbial 
resistance, because the bacterium should completely change the composition of 
the cytoplasmic membrane; an event that would cause significant harm to the 
microorganism itself. However, bringing AMPs to the clinical development 
requires to overcome some of their limitations, e.g. low biostability, cytotoxicity 
and the difficulty in reaching the infection site at active concentrations. These 
disadvantages remain to be solved before a breakthrough in the search for new 
antibiotic compounds. 
  
In the last years, a frog-skin derived AMP named Esc(1-21) was studied for its 
antimicrobial activity against a feared human pathogen, i.e. the Gram-negative 
bacterium P. aeruginosa (Luca, Stringaro et al. 2013). It was previously 
demonstrated by CD spectroscopy that Esc(1-21) adopted an α-helical 
conformation when tested in PE/PG liposomes (7:3 w/w) mimicking the anionic 
nature of the plasma membrane of Gram-negative bacteria. As demonstrated by in 
vitro assays, Esc(1-21) displayed a higher activity against Gram-negative bacteria 
compared to Gram-positive ones. This is presumably due to its own biophysical 
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properties. Structure-activity relationship studies have demonstrated that several 
parameters can influence the spectrum of action and the potency of α-helical 
AMPs, e.g. the amino acid sequence, the length, the net charge, the overall 
hydrophobicity, the amphipathicity, the α-helical content, and the oligomeric state. 
All of these parameters are strictly related and slightly modifications in one of 
them can result in significant changes in one or more of the others. Some studies 
have proved that peptide’s helicity is an important factor for the perturbation of 
biological membranes and for the peptide’s microbicidal activity against Gram-
positive bacteria (Giangaspero, Sandri et al. 2001). For these reasons, an analog 
of Esc(1-21) bearing three strongly helicogenic Aib residues in its primary 
structure was designed and synthesized. In order to confer the peptide a higher 
resistance to proteases (e.g. aminopeptidases and endopeptidases) and a higher α-
helical content, three Aib residues were used to replace the N-terminal amino acid 
(Gly1 → Aib1) as well as the internal lysine 10 (i.e. Lys10 → Aib10) and Gly 18 
(Gly18 → Aib18). From the data obtained by CD spectroscopy [Fig. 13], at 
increasing concentrations of TFE (from 20% to 50%), the Aib-analog appeared to 
be much more helical with respect to the parent peptide. Furthermore, the analog 
[Aib1,10,18]-Esc(1-21) acquired a greater antibacterial activity against Gram-
positive bacteria, while maintaining its efficacy against Gram-negative strains and 
yeasts. It is not easy to give a clear explanation to the different behavior of the two 
peptides against the three different classes of microorganisms. 
Differences in the phospholipid composition of the membrane of these 
microorganisms as well as in the organization of their cell wall could be the main 
reason accounting for the different activities. In fact, before reaching the target 
cytoplasmic membrane, AMPs need to interact with the lipopolysaccharides-outer 
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membrane in Gram-negative bacteria or with the peptidoglycan/glucan-rich layer 
in the cell wall of Gram-positive bacteria/yeasts, respectively. Probably, more 
stringent structural requirements of [Aib1,10,18]-Esc(1-21) may favor its 
translocation through the peptidoglycan barrier into the plasma membrane of 
Gram-positive bacteria. This may in part justify its lower MIC values compared 
to those of the parent peptide (See Tab. 5).  
Yet, a higher α-helicity resulted in increased cytotoxicity (at a peptide 
concentration range from 16 PM to 64 PM) against some eukaryotic cell lines (i.e. 
HaCaT and A549 cells). This is in agreement with previous studies showing that 
both α-helix conformation and its stability are crucial factors for mammalian 
membrane perturbation and cell lysis (Gazit, Lee et al. 1994), (Shai and Oren 
1996). However, at the antimicrobial concentrations of 2 PM and 4 PM, 
[Aib1,10,18]-Esc(1-21) turned out to be harmless as the parent peptide. Overall, on 
the basis of these results, it can be stated that the insertion of three Aib residues in 
Esc(1-21) leads to the production of an analog with a greater activity against 
Gram-positive bacteria without increasing its cytotoxicity at those concentrations 
inhibiting bacterial growth (see Tab. 5). Nevertheless, due to the toxicity of 
[Aib1,10,18]-Esc(1-21) towards human cells at concentrations higher than the MICs, 
it would be better to develop this peptide not for clinical usage, but in the 
agriculture field for the formulation of biocides to prevent contamination of 
agriculture lands by both Gram-positive and Gram-negative bacteria. 
 
Another approach used in this thesis to simultaneously decrease the susceptibility 
of Esc(1-21) to proteolytic enzymes and its cytotoxicity, was the incorporation of 
D-amino acids in the peptide sequence. This is because D-amino acids: (i) are 
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resistant to animal proteases (Weinstock, Francis et al. 2012) and (ii) are known 
to be “D-helix breakers” (Grieco, Carotenuto et al. 2013). More specifically, a 
diastereomer of Esc(1-21) containing D-Leu14 and D-Ser17 [Esc(1-21)-1c)] was 
designed and synthesized. The effects of these two L- to D-amino acids 
substitution in Esc(1-21) were studied on both structural and biological activities 
of the peptide and compared with those of the wild-type Esc(1-21). As 
demonstrated by CD analysis, both peptides adopted an α-helix conformation in 
anionic and zwitterionic environments, e.g. SDS and DPC, respectively. However, 
compared to Esc(1-21), the insertion of the two D-amino acids significantly 
reduced the α-helical content of the peptide in zwitterionic lipids mimicking the 
electrically-neutral membrane of mammalian cells. This can explain the 
significantly reduced cytotoxicity of the diastereomer to different types of human 
cells, compared to Esc(1-21) or to the more helical and more cytotoxic Aib-analog.  
Remarkably, this change in the secondary structure slightly affected the 
antibacterial activity of the peptide against the planktonic form of P. aeruginosa, 
which correlates to other examples in the literature (Oren and Shai 1997) . In 
addition, the diastereomer resulted to be (i) more effective against the sessile form 
of P. aeruginosa, which is much more difficult to eradicate and (ii) more stable in 
human serum. All together these results contribute to make Esc(1-21)-1c a more 
promising candidate for future pharmaceutical preparations against Pseudomonas-
induced infections.  
 
Amino acids replacement is not the only strategy to increase the stability of a 
peptide to proteolytic degradation. Moreover, this approach does not allow a 
peptide to overcome biological barriers (e.g. mucus, skin layers) before reaching 
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the site of infection at high active concentration. A different biochemical approach 
to this purpose is given by the use of nano-systems. It is increasingly evident from 
the literature that the use of nanoparticles has revolutionized the field of 
biomedicine (Cabuzu, Cirja et al. 2015). Among the various nanoparticles 
synthesized in recent years, gold nanoparticles (AuNPs) have attracted most 
attention due to their small size, high solubility and stability. Non-functionalized 
AuNPs have been shown to be biocompatible, chemically inert and biologically 
harmless because of the gold elemental properties (Connor, Mwamuka et al. 
2005), (Williams, Ehrman et al. 2006). It is now known that the reported 
antibacterial activity of non-functionalized AuNPs can be attributable to chemical 
compounds formed during NPs synthesis and not completely removed from them 
(Zhang, Shareena Dasari et al. 2015). AuNPs are one of the most used NPs in 
diagnostic and biomedicine (Reznickova, Novotna et al. 2015), (Tsai, Lu et al. 
2015).  
However, the designed AuNPs@Esc(1-21) have represented an innovation: for the 
first time, it has been shown how a chemical conjugation of an AMP via a PEG 
linker to AuNPs (synthetized by the citrate reduction of gold), increases its 
antimicrobial activity while retaining its mode of action and harmless effect on 
human keratinocytes. As pointed out in tab. 11, AuNPs@Esc(1-21) were more 
efficient in killing both forms of P. aeruginosa compared to the activity explicated 
by the same concentration of the free peptide. This is indicated by the lower 
MBC50 and MBEC50 values (see tab. 11) compared to those found for Esc(1-21) 
and this is likely due to the higher local concentration of peptide molecules at the 
site of bacterium-NPs contact.  
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Indeed, packaging peptide molecules within the same NP would enable not only 
to protect the peptide from proteolytic degradation, but also to enhance its local 
concentration reaching doses much higher than dose achievable after 
administration of free peptides. It is worthwhile noting that the conjugation of 
Esc(1-21) to AuNPs@PEG did not affect the bacterial membrane-perturbation of 
the peptide. An evidence to support this statement was provided by the results of 
the Sytox Green assay and the electron microscopy analysis, which showed the 
leakage of cytosolic compounds already after 8 min from peptide addition to the 
bacteria. In addition, the SEM/TEM images proved that the bare AuNPs@PEG 
were not detected on the bacterial cell surface. This highlights that Esc(1-21) is 
the driving force allowing AuNPs@Esc(1-21) to reach the bacterial membrane 
and to perturb it.  
Furthermore, the conjugation of the peptide to AuNPs@PEG did not result in 
higher cytotoxicity and was found to preserve the peptide’s capability to stimulate 
cell migration in a pseudo-“wound” healing assay on a keratinocytes monolayer. 
This suggests their ability to accelerate recovery of a wound in a skin layer, 
following bacterial infection. Importantly, it was recently demonstrated that 
AuNPs can pass through different types of animal tissues and through the stratum 
corneum barrier, depending on their size, shape and charge (Greish, Thiagarajan 
et al. 2012). All these results and considerations make AuNPs@Esc(1-21) 
attractive nano-formulation for the topical treatment of skin infections.  
 
Remarkably, P. aeruginosa not only colonizes ulcers and skin wounds but also the 
mucus in the lungs of cystic fibrosis (CF) patients, leading to serious chronic 
infections that classical antibiotics can hardly reach and eradicate. It is therefore 
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necessary a pharmaceutical formulation able to reach the site of infection and to 
provide a prolonged drug release, avoiding multiple drug administrations.  
Many studies have been conducted in recent years to characterize PLGA NPs for 
pulmonary drug release. Their small size makes them suitable molecules to 
overcome the airway barrier and to target specific lung cells. A previous study 
demonstrated that modulation of NPs’ size and surface with PVA and CS can be 
of great help to facilitate their transport through the mucus (Ungaro, d'Angelo et 
al. 2012).   
As for the AuNPs@Esc(1-21), the CS/PVA-PLGA NPs were designed to (i) 
protect the peptide from proteolytic degradation; (ii) let it reach the site of 
infection at high concentrations and to (iii) provide a sustained peptide release in 
order to prolong the peptide’s therapeutic effect. In this case, however, CS and 
PVA-PLGA NPs were loaded with a model AMP (i.e. Col) currently employed 
for treatment of P. aeruginosa lung infections in CF patients. Both formulations 
were embedded into an inert carrier forming inhalable dry powders (Nano-
embedded microparticles, NEM). 
The two engineered-NPs showed a high percentage of entrapment efficiency (≥ 
60% of Col) but a difference in drug release. PVA-modified NPs provided a slow 
and sustained Col release lasting for 15 days; in comparison, CS-modified NPs 
showed an initial higher “burst” followed by a slower release kinetics (see Fig. 
31). Furthermore, the Col-CS NPs diffused more easily through an artificial CF 
mucus than Col-PVA NPs, whereas the free Col did not succeed in penetrating it. 
This in an important outcome for the future treatment of Pseudomonas-induced 
infection in CF patients: indeed, the resistance of the biofilm form of 
Pseudomonas to the currently used antibiotics is mainly due to their inability to 
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penetrate the mucus made of alginates and other extracellular polysaccharides. 
Interestingly, it was demonstrated that both NEMs formulation were able to 
penetrate the bacterial biofilm and to release Col overtime (72 h). Moreover, both 
CS and PVA modified NPs were found to enhance the activity of Col against P. 
aeruginosa biofilm at long-term (up to 72 h), while the free peptide was no longer 
effective beyond 24 h. The gradual release of Col from NEMs, especially from the 
PVA-NPs, allowed a prolonged exposure of the drug to the biofilm communities, 
with a resulting higher efficiency in biofilm eradication at long-time.  
Taken all together, these results suggest that engineered microembeeded PLGA 
NPs represent a fascinating technical approach to encapsulate novel antimicrobials 
such as Esc(1-21) for treatment of P. aeruginosa lung infection. Future studies 
will focus on the design and manufacturing of these type of formulations, likely 
containing Esc(1-21) for the development of new antipseudomonal strategies.  
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5. Conclusions and future perspectives 
Presently, AMPs represent one of the most promising future strategies for the 
development of new antimicrobial compounds to eradicate bacterial infections, 
most of which have become resistant to the available antibiotics.  
In spite of their great potential as templates for the manufacturing of new drugs, 
only a small number of AMPs has entered into clinical trials. This is mainly due 
to some disadvantages including low peptide bioavailability, high toxicity, and 
high susceptibility to proteolytic degradation. On the basis of the structure-activity 
relationship (SAR) studies on thousands of AMPs, it has been possible to know 
the main physicochemical parameters playing a crucial role in their mechanism of 
action. 
Furthermore, the rapid progress in the field of nanotechnology has suggested the 
usage of peptide-coated nanoparticles as valuable carriers not only to prolong the 
peptide’s half-life but also to overcome biological barriers (e.g. lung mucus, 
biofilm extracellular matrix) that a peptide needs to face before reaching its target 
site.  
 On the basis of this knowledge, either substitution of natural amino acids with 
non-coded residues or peptides conjugation to inorganic/polymeric NPs have been 
used in this work to rationally optimize the antimicrobial properties of cationic 
peptides, e.g. the frog-skin derived AMP Esc(1-21) and the currently used colistin.  
Importantly our results have indicated that these approaches represent encouraging 
methodologies to improve the antimicrobial properties of AMPs and for the 
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generation of new peptide-based formulation for an efficient treatment of different 
types of infectious diseases. 
Taken all together, these results encourage us to continue to investigate the 
interesting biological properties of Esc(1-21) analogs, e.g. Esc(1-21)-1c,  to better 
understand the biochemical parameters responsible for their antimicrobial 
features. In addition, these peptides could be used for the development of novel  
gold and polymeric nanoparticles-based therapeutic formulation.   
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6. Materials and Methods 
6.1 – MATERIALS 
Chemically synthesized Esc(1-21) and the diastereomer Esc(1-21)-1c were 
purchased from Selleck Chemicals (Houston, TX, USA). [Aib1,10,18]-Esc(1-21) 
was synthesized by the group of Dr. Marco Crisma, University of Padova.  
Dulbecco’s modified Eagle’s medium (DMEM), heat-inactivated fetal bovine 
serum (FBS), non–essential amino acids (NEAA), sodium pyruvate (100 mM), 
penicillin/streptomycin, glutamine and gentamycin were from Euroclone (Milan, 
Italy). Sytox Green was obtained from Molecular Probes (Leiden, The 
Netherlands); 3(4,5-dimethylthiazol-2yl)2,5-diphenyltetrazolium bromide 
(MTT), Hank’s buffer, colistin sodium sulphate (Col), polyvinyl alcohol (PVA), 
Triton-X 100 and trypsin from bovine pancreas were from Sigma-Aldrich (St. 
Louis, MO). Ultrapure chitosan (CS) was obtained from NovaMatrix (Oslo, 
Norway). All other chemicals were reagent grade. 
6.2 – MICROORGANISMS 
The microorganisms used for the antimicrobial assays were:  
x Gram-negative bacteria: the reference Pseudomonas aeruginosa ATCC 
27853 and the clinical isolates P. aeruginosa AA11, KK1 and TR1. In 
addition, the reference Acinetobacter baumannii ATCC 19606, 
Escherichia coli D21, E. coli ATCC 25922 and Yersinia 
pseudotuberculosis YPIII were used. Furthermore, the P. aeruginosa 
PAO1 strain carrying plasmid pPrsal190 (Rampioni, Schuster et al. 2007), 
(Rampioni, Polticelli et al. 2007), kindly provided by Prof. Livia Leoni 
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(Roma Tre University, Rome, Italy), was used for the β-galactosidase 
activity assays.    
x Gram-positive bacteria: the reference Staphylococcus epidermidis ATCC 
12228 and Bacillus megaterium Bm11 as well as the clinical isolates S. 
aureus 6938, S. capitis 1, S. epidermidis 21 and S. hominis 1.  
x Yeasts: the reference Candida albicans ATCC 10231 and C. guiller 
mondii from the frog natural flora (Mangoni, Miele et al. 2001). 
  
6.3 – CELL CULTURES 
The human type II alveolar epithelial cell line A549 (from the American Type 
Culture Collection, Manassas, Va), the human immortalized keratinocytes 
(HaCaT) cell line and the murine Raw 264.7 macrophage cell line were employed. 
Macrophages and A549 cells were cultured in DMEM supplemented with 10% 
FBS, 2 mM L-glutamine and antibiotics (0.1 mg/mL of penicillin and 
streptomycin) at 37 °C and 5 % CO2 in 25-cm2 flasks. In the case of macrophages, 
NEAA and sodium pyruvate were also added. For HaCaT cells, 4 mM L-
glutamine and 0.05 mg/mL of gentamicin were added to the medium. 
 
6.4 – METHODS 
6.4.1 – Circular dichroism (CD) spectroscopy 
CD spectra of Esc(1-21) and [Aib1,10,18]-Esc(1-21) were measured on a 
Jasco (Hachioji City, Japan) model J-715 spectropolarimeter equipped 
with a Haake thermostat, while CD spectra of Esc(1-21) and Esc(1-21)-1c 
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were measured on a Jasco 815. A fused quartz cell of 0.1 mm path length 
(Hellma, Mühlheim, Germany) was used. Measurements were collected at 
25 °C and at 0.1 nm wavelength intervals in the 190- 300 nm range. 
 
6.4.2 – Liposomes preparation 
Peptide-membrane interaction can be investigated by the use of liposomes 
as model membranes, due to their bilayer structure, which is in principle 
identical to the lipid organization of biological membranes (Mouritsen 
2011). Liposomes were prepared by dissolving the lipids in a 2:1 (v/v) 
chloroform/methanol solution, i.e. phosphatidylethanolamine/ 
phosphatidylglycerol (PE/PG) at a ratio 7:3 (v/v). The solvents were then 
evaporated under reduced argon atmosphere until a thin film was formed. 
The lipid film was hydrated with CF solution [Fig. 37] in 10 mM phosphate 
buffer containing 140 mM NaCl and 0.1 mM EDTA, pH 7.4. CF was 
entrapped inside liposomes at a self-quenching concentration, i.e. 30 mM. 
The liposome suspension was subjected to 10 freeze and thaw cycles and 
extruded through two stacked polycarbonate membranes with 100 nm 
pores to obtain unilamellar vesicles. The final lipid concentration was 
determined by the Stewart phospholipids assay (Stewart 1980).  
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Figure 37 - Chemical structure of carboxyfluorescein 
 
The obtained liposomes were separated from the free dye by gel filtration 
on a 40 cm Sephadex G-50 column. 
 
6.4.3 – AuNPs: synthesis and characterization  
AuNPs were synthesized by the citrate reduction method as previously 
described (J. Turkevitch, P.C. Stevenson, et al 1951), (G. Frens 1973). 
Hydrogen tetrachloroaureate (III) (0.235 mmol) was dissolved in 200 mL 
of Milli-Q water and magnetically stirred under reflux. Sodium citrate 
dehydrate was then added [Fig. 38]. The solution was kept under ebullition 
and protected from light for 30 min.  
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Figure 38 - Schematic representation of the synthesis of AuNPs 
  
The obtained AuNPs were characterized by ultraviolet-visible (UV-vis) 
spectroscopy (Cary 100, Agilent) due to their surface plasmon resonance (λmax, 
519 nm) and by transmission electron microscopy (TEM, FEI Tecnai T20). A 
molar extinction coefficient (λ = 450) of 1.76 x 108 was used to determine the 
particles concentration (Haiss, Thanh et al. 2007). For AuNPs stabilization, a 
bifunctional poly(ethylene glycol) [SH-EG(8)-(CH2)2-COOH] (PEG) was used 
(Conde, Ambrosone et al. 2012). After an incubation time of 16 h at room 
temperature, the excess of PEG chains were removed by centrifugation at 14,000 
x g for 30 min at 4 °C, thrice. Twenty pmol of AuNPs conjugated to PEG 
(AuNPs@PEG) were incubated with different amounts and ratios of EDC and 
sulfo-NHS [Fig. 39] in 1 mL of 10 mM 2-(N-morpholino)ethanesulfonic acid 
(MES), pH 6.1.  
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Figure 379 - Chemical structure of EDC (left) and sulfo-NHS (right). 
 
After activation of PEG in the best condition to prevent the aggregation of AuNPs, 
different amounts of Esc(1-21) (from 1.5 to 4 µg) were added to the mixture and 
incubated at room temperature for 2 h. After removing the excess of unbound 
peptide by centrifugation as above, the stability of AuNPs conjugated with the 
peptide [AuNPs@Esc(1-21)] was assessed by UV-vis spectroscopy and the 
amount of 2 µg was chosen for all the experiments. The supernatant was recovered 
and analyzed for the amount of Esc(1-21) by the colorimetric microBCA  protein 
assay reagent kit (Pierce, Rockford, IL), according to the manufacture instructions. 
ζ-potential was performed on a Malvern Zetasizer instrument at 25 °C.  
 
6.4.4 - CS/PVA-Col nanoparticles and nano-embedded microparticles: 
synthesis and characterization     
Col-loaded nanoparticles were prepared at 2% theoretical loading (2 mg of Col 
per 100 mg of NPs) by a modified emulsion/solvent diffusion technique (Ungaro, 
d'Angelo et al. 2012). A water in oil emulsion was achieved adding 100 µL of an 
aqueous Col solution (2 mg/ml) to 1 mL of PLGA-containing methylene chloride 
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(1% w/v) under vortex mixing (2400 min-1, Heidolph, Germany). The emulsion 
was then added to 25 mL of an external diffusion phase leading to an immediate 
polymer precipitation in the form of NPs. The external diffusion phase was 
composed by an ethanol:water mixture (1:1 v/v) containing PVA (PVA/PLGA 
ratio 1:1 w/w) or CS (CS/PLGA ratio 1:20 w/w). The dispersion was kept under 
stirring at room temperature for 10 min; afterwards, residual organic solvent was 
evaporated under vacuum at 30 °C (Rotavapor®, Heidolph VV2000, Germany). 
NPs were isolated by centrifugation at 7000 rcf for 20 min at 4 °C and dispersed 
in ultrapure water. The morphology of obtained NPs was assessed by TEM.  
Nano-embedded microparticles (NEM) were produced by co-spray drying Col-
loaded NPs and an inert carrier (lactose) as follows: NPs were dispersed in an 
aqueous solution of lactose and then diluted with ethanol (ethanol/water ratio 1:1) 
up to a NPs concentration of 1 mg/mL and carrier concentration of 2% (w/v). The 
final dispersion was processed in a Mini Spray Dryer Büchi 190 (Flawil, 
Switzerland) equipped with a high-performance cyclone for the recovery of small 
powder amounts.    
 
6.5 – ANTIMICROBIAL ACTIVITY 
6.5.1 - Determination of the minimal growth inhibitory peptide 
concentration (MIC) 
The antimicrobial activity of Esc(1-21) and [Aib1,10,18]-Esc(1-21), was evaluated 
by performing the microbroth dilution assay in sterile 96-well plates, as outlined 
by the Clinical and Laboratory Standards Institute (2001), to determine the MIC. 
Serial 2-fold dilutions of peptide in 50 μL of Muller-Hinton (MH) broth were 
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prepared through the wells of the microtiter plate. Aliquots (50 μL) of bacteria at 
a concentration of 2x106 (CFU)/mL in MH were added. MIC was defined as the 
lowest peptide concentration at which 100% inhibition of growth is visible after 
16-18 h at 37°C. The same procedure was followed with yeasts in Winge medium 
(Valenti, Visca et al. 1985) using a final concentration of 3.5 x 104 CFU/mL and 
an incubation time of 18 h at 30 °C.  
6.5.2 - Determination of the minimal bactericidal peptide concentration 
(MBC)   
Bacteria were grown in LB broth at 37 °C till a mid-log phase which was 
aseptically monitored by absorbance at 590 nm (A590 = 0.8) with an UV-1700 
Pharma Spec spectrophotometer (Shimadzu, Tokyo, Japan).  
For the studies on Esc(1-21) and its diastereomer Esc(1-21)-1c, the minimal 
peptide concentration causing at least 99.9% bacterial killing was determined as 
follows: about 1 x 105 in 100 µL of PBS were incubated at 37 °C with the peptides 
in serial two-fold dilution. Aliquots (10 µL) were withdrawn after 30 min, diluted 
in LB and spread onto LB-agar plates. After overnight incubation, the number of 
CFU was counted. 
Differently, for the experiments with AuNPs@Esc(1-21), the minimal peptide 
concentration causing at least  50% killing of bacteria (MBC50) was determined. 
About 4 x 107 bacterial cells were incubated at 37 °C with serial twofold dilution 
of Esc(1-21), AuNPs@Esc(1-21) and AuNPs@PEG for 20 min. Aliquots were 
withdrawn and diluted in LB and spread onto LB-agar plates. After overnight 
incubation, the number of CFU was counted. 
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6.6 – PEPTIDE STABILITY TO PROTEOLYSIS  
To evaluate the stability of Esc(1-21) (free or conjugated to AuNPs@PEG) to a 
proteolytic enzyme, i.e. trypsin, a concentration corresponding to 2 × MBC50 of 
the free peptide (2 μM) or AuNPs@Esc(1-21) (10 nM) in 100 mM sodium 
phosphate buffer (NaPB) was pre-incubated with trypsin (0.02 μg/mL) for 100 
min at 37 °C under mild agitation in a volume of 50 μL. Afterwards, 50 μL of 
bacteria in NaPB were added to reach a final mixture volume of 100 μL and a cell 
density of about 4 × 108 CFU/mL in the presence of Esc(1-21) or AuNPs@Esc(1-
21) at their MBC50 (1 μM and 5 nM, respectively). After 20 min treatment, aliquots 
were withdrawn and plated for counting. 
6.7 – ANTIBIOFILM ACTIVITY 
Biofilm formation was performed by adapting the procedure described in 
(Falciani, Lozzi et al. 2012), using the Calgary Biofilm Device (Innovotech, 
Innovotech Inc. Edmonton, Canada) as follows: 96-well plates, each well 
containing 150 μL of the bacterial inoculum (1 x 107 CFU/mL) in LB medium, 
were sealed with 96-pegs-lid on which biofilm can build up. The plates were then 
incubated for 20 h in a humidified incubator at 35 °C under agitation at 125 rpm. 
Each pegs-lid was rinsed twice with PBS and transferred to a “challenge plate” 
each well containing 200 μL of Esc(1-21), Esc(1-21)-1c, AuNPs@PEG or 
AuNPs@Esc(1-21) for  2 h. As reported in literature (Luca, Stringaro et al. 2013), 
three different assays can be performed to evaluate the antibiofilm activity of a 
drug: (i) absorbance measurement of reduced MTT; (ii) CFU counting; and (iii) 
crystal violet (CV) staining.  
94 
 
For the experiments with Esc(1-21) and its diastereomer,  the antibiofilm activity 
was evaluated by determining the amount of viable biofilm cells. This was 
achieved by measuring the reduction of MTT to its insoluble formazan [Fig. 40]. 
MTT is a tetrazolium salt, which is reduced to an insoluble formazan product, by 
mitochondrial reductases, giving a purple color. The intensity of the color is 
directly proportional to the number of viable cells. 
 
Figure 40 - Reduction of the yellow tetrazole to purple insoluble formazan, by metabolically-active 
cells. 
After peptide treatment, the peg-lids were rinsed with PBS, transferred to another 
96-wells plate, each well containing 1 mg/mL MTT, and incubated for 4 h at  
37 °C. SDS (5 % final concentration) was then added to stop the reaction and to 
solubilize the formazan crystals. Bacterial viability was determined by absorbance 
measurements at 595 nm and calculated with respect to the control.  
 
In the case of AuNPs@Esc(1-21), to avoid any possible interference on the 
absorbance of reduced MTT by the red color of AuNPs suspension, the antibiofilm 
activity  was determined by CFU counts. The minimal biofilm eradication 
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concentration (MBEC50) was defined as the lowest drug concentration sufficient 
to cause at least 50% killing of biofilm cells within 2 h. After 
peptide/AuNPs@Esc(1-21) treatment, pegs were washed with  PBS, broken from 
the lid and transferred into eppendorf tubes containing 200 µL of PBS. Samples 
were sonicated three times for 10 min in an ultra-sonic water bath to detach 
bacterial cells from the pegs. Aliquots were withdrawn and spread onto LB-agar 
plates for colony counting. 
 
Differently, with regards to CS/PVA-Col loaded nanoparticles, the effect on total 
biofilm biomass (viable cells plus extracellular matrix) was determined by the CV 
staining (Luca, Stringaro et al. 2013). In this case, after biofilm formation as 
described above, the peg-lids were rinsed twice with PBS and transferred into 
“challenge plates” each well containing 200 µL of free Col, Col-CS and Col-PVA 
NEM. The plates were then incubated for 24 h, 48 h and 72 h at 37 °C in a 
humidified incubator. Afterwards, the pegs were fixed in 99% methanol for 15 
min at room temperature, and stained with CV solution (0.05% in water) for 15 
min. Bound CV was released from pegs using 33% acetic acid. The absorbance 
was measured at 600 nm.  
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6.8 - MECHANISM OF ACTION: MEMBRANE PERMEABILIZATION 
ASSAYS 
6.8.1 – β-galactosidase assay  
The ability of Esc(1-21) and its diastereomer Esc(1-21)-1c to damage the 
cytoplasmic membrane of P. aeruginosa cells was determined by measuring the 
extracellular leakage of the cytosolic enzyme β-galactosidase, using ortho-
Nitrophenyl-β-galactoside (ONPG) as a substrate (Marcellini, Borro et al. 2009) 
[Fig. 41]. P. aeruginosa PAO1, that constitutively expresses the β-galactosidase, 
was grown at 37 °C in LB till a mid-log phase, washed twice, centrifuged for 10 
min (1,4 x g) and resuspended in 0.1 M NaPB at OD590 = 0.8 . About 1x106 
bacterial cells (in 100 μl NaPB) were incubated with two different concentrations 
of Esc(1-21) and Esc(1-21)-1c, i.e. 10 µM and 20 µM, for 30 min at 37 °C. 
Controls were bacteria without peptide, whereas the maximal membrane 
perturbation was obtained after treating bacteria with the highest peptide 
concentration used (20 μM) followed by the addition of 1 mM 
ethylenediaminetetraacetic acid (EDTA) + 0,5% Triton X-100 (final 
concentration) to completely destabilize the lipopolysaccharide outer membrane 
and to solubilize the phospholipid bilayer of the cytoplasmic membrane 
(Uccelletti, Zanni et al. 2010). At the end of the incubation time, aliquots were 
withdrawn, diluted in LB, and spread on LB plates for counting. Afterwards, 450 
μL of NaPB were added to the remaining bacterial suspension, which was passed 
through a 0.2-μm filter. The hydrolysis of 2 mM ONPG, added to the culture 
filtrate, was recorded at 420 nm using a spectrophotometer (UV-1700 Pharma 
Spec Shimadzu). 
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Figure 41 - β-galactosidase hydrolysis of the colorless ONPG to produce galactose and the yellow 
o-nitrophenol, which absorbs light at 420 nm. 
6.8.2 – Carboxyfluorescein leakage assay 
Peptide-membrane interaction can be investigated by the use of liposomes 
as model membranes, due to their bilayer structure, which is in principle 
identical to the lipid organization of biological membranes.  
In the CF leakage assay, a concentration of lipid vesicles of 200 µM and 
different peptide concentrations of Esc(1-21) and Esc(1-21)-1c were used. 
After peptide addition, CF leakage from the damaged liposomes was 
recorded at λem=520 nm with λexc= 488 nm and monitored for 30 min. The 
percentage of CF released was calculated with respect to the control 
(untreated liposomes). A schematic representation of CF-encapsulated 
liposomes is shown in [Fig. 42]. 
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Figure 42 - Schematic representation of a CF-encapsulated liposome 
 
 
6.8.3 – Sytox Green assay 
The ability of AuNPs@Esc(1-21) to affect the membrane permeability of P. 
aeruginosa cells, was assessed by the Sytox Green assay in microtiter plates as 
previously described for the free peptide (Luca, Stringaro et al. 2013). Briefly, 
bacterial cells (4x108 CFU/mL) in NaPB supplemented with 1 μM Sytox Green 
[Fig. 43] were added to each well.  
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Figure 383 - Chemical structure of Sytox Green 
 
Then, AuNPs@Esc(1-21), AuNPs@PEG or free Esc(1-21) were added at the 
indicated concentration. For the control sample, peptide solvent (water) was used. 
The increase in fluorescence, owing to the binding of the dye to intracellular DNA, 
was measured every min for 30 min at 37 °C with a microplate reader (Infinite 
M200; Tecan, Salzburg, Austria) at excitation and emission wavelengths equal to 
485 and 535 nm, respectively. Final values were reported as ratio of each value 
(measured within 30 min) to the initial one measured after 1 min. Considering the 
absorbance of AuNPs@PEG as a background, the measurements of these samples 
were properly subtracted from those containing AuNPs@Esc(1-21). 
 
6.9 – ELECTRON MICROSCOPY 
To visualize the membrane-perturbing activity of AuNPs@Esc(1-21), SEM and  
TEM analysis were performed. 
 
For SEM analysis, P. aeruginosa was grown overnight at 37 °C in LB. 
After 10 min centrifugation at 1400×g, the bacterial pellet was 
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resuspended in NaPB to an OD590 = 0.8. The bacterial culture was passed 
through a syringe to avoid possible clumps. Approximately 4 × 107 
bacterial cells in a total volume of 100 μL were incubated with 
AuNPs@Esc(1-21) or AuNPs@PEG at 37 °C in a thermomixer under 
agitation for different times (1 min, 8 min and 15 min). Controls were 
buffer-treated bacterial cells. At the indicated time intervals, samples were 
centrifuged at 6000×g for 10 min and washed three times with NaPB. 
Afterwards, they were fixed with 2.5% glutaraldehyde (100 μL) in NaPB 
for 2 h at room temperature. The samples were then centrifuged at 
12,000×g for 10 min and washed three times as above. Samples were 
analyzed using an Environmental scanning electron microscope (ESEM, 
Quanta FEG 250) with a wet scanning-transmission electron microscopy 
(wet-STEM) detector at high vacuum mode. Specimens were mounted in 
a Quantifoil® holey carbon film copper grids and examined with a 
working distance between 7 and 10 mm and an accelerating voltage of 20 
kV.  
 
For TEM analysis, bacterial samples were similarly prepared as described 
above but in a total volume of 1 mL. After washing and fixing cycles (as 
for SEM, but in a total volume of 1 mL), the pellets were subsequently 
embedded in 1.5% agar (Panreac); post fixed in 2% osmium tetroxide for 
1 h at room temperature and stained in 1% uranyl acetate in the dark for 2 
h at 4 °C. Then, they were rinsed in distilled water, dehydrated in ethanol 
and infiltrated overnight in Durcupan resin (Fluka). Following 
polymerization, embedded cultures were detached from the wells and 
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glued to araldite blocks. Finally, ultra-thin sections (0.08 μm) were cut 
with a diamond knife (Leica), stained with lead citrate (Reynolds solution) 
and examined under a 200 keV transmission electron microscope FEI 
Tecnai T20 (FEI Europe) operating at 60 keV. 
 
6.10 - CYTOTOXICITY 
The effect of Esc(1-21), [Aib1,10,18]-Esc(1-21), Esc(1-21)-1c and 
AuNP@Esc(1-21) on the viability of mammalian cells was determined by the 
inhibition of MTT reduction to insoluble formazan by mitochondrial 
reductase. About 4 x 104 cells resuspended in the corresponding culture 
medium supplemented with glutamine, 2% FBS without antibiotics were 
plated in each well of a microtiter plate. After overnight incubation at 37 °C 
and 5% CO2 atmosphere, the medium was replaced with fresh medium 
containing the peptides at different concentrations. The plates were then 
incubated for 2 or 24 h at 37 °C and 5% CO2 atmosphere. After incubation 
time, the medium was removed and replaced with Hank’s buffer containing 
0.5 mg/mL MTT. After 4 h incubation, the formazan crystals were dissolved 
by adding acidified isopropanol. The viability was determined by absorbance 
measurements at 570 nm using a microplate reader reader (Infinite M200; 
Tecan, Salzburg, Austria). Cell viability was calculated with respect to the 
control according to the formula: 
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      where the blank is given by samples without cells and not treated with the 
peptides. 
6.11 - CELL MIGRATION ASSAY 
The ability of AuNPs@Esc(1-21) to stimulate migration of keratinocytes was 
studied according to a modified scratch assay (Di Grazia, Cappiello et al. 
2015). Briefly, about 4 x 104 HaCaT cells suspended in DMEM  supplemented 
with 4 mM glutamine (DMEMg) 10% FBS were seeded on each side of an 
ibidi culture insert for live cell analysis (Ibidi, Munich, Germany). Inserts were 
placed into wells of a 24-wells plate and incubated at 37 °C and 5% CO2 to 
allow cells grow to confluence. Afterwards, inserts were carefully removed to 
create a cell-free area (pseudo-wound) of approximately 500 μm. Afterwards, 
300 μL of DMEMg supplemented with AuNPs@Esc(1-21) or AuNPs@PEG 
or the free peptide, were added. Control samples were cells treated with 
DMEMg in the presence of peptide solvent (water). Cells were allowed to 
migrate for 9 h in an appropriate incubator, at 37°C and 5% CO2. At different 
time intervals, fields of the pseudo-wound area were visualized under an 
inverted microscope (Olympus CKX41) at ×4 magnification and 
photographed with a Color View II digital camera. The percentage of cell-
covered area at each time was determined by WIMASIS Image Analysis 
program. 
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6.12 – STATISTICAL ANALYSIS 
Quantitative data were expressed as the mean ± SEM or SD. Statistical 
analysis was performed using Student's t test or two-way analysis of variance 
(ANOVA), with PRISM software (GraphPad, San Diego, CA). Differences 
were considered to be statistically significant for p < 0.05. The levels of 
statistical significance are indicated in the legend to figures. 
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